

Index

- Abnormal Involuntary Movement Scale, 58
 Abraham, Karl, 115–116, 375
 Abreaction process, 36, 133
 Absence (petit mal) seizure, 298
 Abulia, 47
 Abuse and neglect
 battered children, 360
 of children
 parental characteristics, 360
 socioeconomic risks, 360
 incest
 relations, 361
 socioeconomic consideration, 361
 risk factors for abusers, victims, 361
 sexual harassment, 362
 stalking, 363
 Acamprosate (Campral), 16, 247–248
 Acathexis/cathexis, 49
 Acetylcholine, 11, 75
 nicotinic acetylcholine receptors, 16, 82, 86, 96
 synthesis/metabolism, 10
 Acquired receptive (epileptic) aphasia, 176
 Acrophobia, 47
 Activities of daily living (ADL), 74
 Acute dystonia, from cocaine, 91–92
 Acute inflammatory demyelinating polyneuropathy (AIDP), 346–347
 Acute neuroma, 312
 Acute stress disorder, 119
 Addictions, alcohol-related disorders
 alanine aminotransferase/aspartate aminotransferase, 85
 CAGE questionnaire, 85
 Cloninger types of alcoholism, 85
 comorbidities, 85–86
 effects on sleep, 84
 fetal alcohol syndrome, 86
 gamma-glutamyl transpeptidase (GGT), 85, 86
 idiosyncratic alcohol intoxication, 86
 mechanism of effects, 86
 metabolism of alcohol, 86–87
 one drink equivalents, 87
 prognosis, 87
 psychodynamic theories about, 87–88
 Wernicke-Korsakoff syndrome, 88
 Wernicke's encephalopathy, management, 88
 withdrawal seizures, 84–85
 Addictions, general considerations
 abuse vs. dependence, 81–82
 acting mechanisms of substances, 82
 drug abusers, common mental disorders, 83
 DSM-IV-TR diagnosis
 dependence but not abuse, 82
 substances with no withdrawal, 82
 substance abuse
 common substances, 83
 remission courses, 83
 Addictions, non-alcoholic substance related disorders, 85
 amphetamine/cocaine intoxication and withdrawal, 82, 89–90
 caffeine, mechanism of action, 90
 cannabis
 induced disorders, 90
 mechanism of action, 90
 specific signs/symptoms, 90
 club drugs, 91
 cocaine, 91
 adverse effects, 91–92
 disorders induced by, 93
 use during pregnancy, 92
 date rape drugs, 93
 ecstasy (MDMA), 82, 91, 93–94
 eye/vision specific symptoms
 intoxication/withdrawal, 93
 hallucinogens, 93–94
 disorders induced by, 94
 intoxication, signs/symptoms, 94
 inhalants, 94
 mechanisms of action, 95
 pathological effects, 95
 LAAM (levo-alpha acetyl methadol), 91
 LSD, 82, 91, 93–94, 95
 methamphetamines, 95
 nicotine/nicotine-related disorders, 82, 83, 86, 96
 opioids, 17, 82, 93, 96–97
 dependence (etiology), 97
 intoxication and withdrawal, 97–98
 pregnancy and, 97, 98
 receptors, 98

442 Index

- Addictions, non-alcoholic substance related disorders (*Cont.*)
 phencyclidine (PCP)
 intoxication, signs/symptoms, 98–99
 intoxication, treatment, 99
 receptor mechanism, 99
 substance-specific symptoms, 99
 Adipex-P (phentermine), 260–261
 Adolescent development. *See also* child and adolescent psychiatric disorders; child development
 Freud on, 34
 gender identity, 30
 gender role, 30
 puberty development
 in boys, 33
 in girls, 33–34
 social development model, 30
 stages/classical theories, 27
 concrete operational stage (Piaget), 29
 developmental stages (Piaget), 31
 Adrenergic alpha-2 receptor, 10–11
 Adrenogenital syndrome, 288
 Adverse effects, evaluation and treatment for. *See also* pharmacokinetic interactions
 amantadine, 267
 anticholinergics, 268
 antidepressants, 270
 antipsychotics, 271, 273
 atypical, 272, 275
 benzotropine, 268
 dantrolene, 268–269
 deep brain stimulation, 277
 diphenhydramine, 269
 discontinuation syndromes, 269–270
 electroconvulsive therapy, 276, 281–282
 MAOIs, 270–271
 neuroleptic malignant syndrome, 271
 propranolol, 271–272
 psychosurgery, 280
 Rabbit syndrome, 272
 serotonin syndrome, 273
 SIADH, 273
 tardive dyskinesia, 273–275
 trihexyphenidyl, 275
 Affect flattening, 105
 Affect vs. mood, 47
 Afrin (oxymetazoline), 264
 Agnosia, 47
 finger agnosia, 340
 Agranulocytosis, from antipsychotics, 270
 Agraphia, 47
 alexia without, 308, 339
 AIDS-related disorders
 CNS lymphoma, 292
 complications presentation, 293
 cryptococcus, 292
 cytomegalovirus (CMV), 292–293
 toxoplasmosis, 292, 296
 Ainsworth, Mary, 46
 Akathisia, 18, 47, 271–272, 334
 Akinesia, 47, 336, 338
 Alanine aminotransferase (AAT), 85
 Alcohol-related disorders (addictions)
 alanine aminotransferase/aspartate aminotransferase, 85
 CAGE questionnaire, 85
 Cloninger types of alcoholism, 85
 comorbidities, 85–86
 effects on sleep, 84
 fetal alcohol syndrome, 86
 gamma-glutamyl transpeptidase (GGT), 85, 86
 idiosyncratic alcohol intoxication, 86
 mechanism of effects, 86
 metabolism of alcohol, 86–87
 one drink equivalents, 87
 prognosis, 87
 psychodynamic theories about, 87–88
 Wernicke-Korsakoff syndrome, 88
 Wernicke's encephalopathy, management, 88
 withdrawal seizures, 84–85
 Alexia without agraphia, 308, 339
 Alexithymia, 48
 Alogia (poverty of speech), in schizophrenia, 105
 Alprazolam (Xanax), 236, 237
 Altruism, 372
 Alzheimer, Aloysius, 72–73
 Alzheimer's disease, 21
 dementia with Lewy bodies from, 75–76
 depression and, 77–78
 Down's syndrome and, 175
 fluent aphasia and, 340
 genetic findings, 72
 neuropathology, 72–73
 pharmacologic treatments
 donepezil for, 253–254
 rivastigmine for, 255
 tacrine for, 255
 transcortical aphasia and, 342
 Amafufanyane (culture bound syndrome), 372
 Amantadine (Symmetrel), 267
 Amaurosis fugax, 48
 Ambien/Ambien CR (zolpidem), 246
 Ambivalent attachment (of children), 27–28
 Amitriptyline (Elavil)
 for children and adolescents, 171
 general information, 217–218
 Amnesia
 from acute stress disorder, 119
 from amafufanyane, 372
 cognitive impairment in, 74
 dissociative amnesia, 132–133
 treatment, 134
 etiology, 73
 infantile amnesia, 31, 51
 mammillary body, 73

- paramnesia, 52
 from piblokto, 380
 transient global amnesia, 80, 93, 310
 Amok (culture bound syndrome), 372–373
 Amoxapine (Asendin), 218–219
 Amphetamines (Adderall, Adderall XR), 82, 91, 95,
 256–257
 Amphotericin, for cryptococcus infection, 292
 Amprenavir, 262
 Amygdala, 7
 amnesia and, 73
 anatomy of, 2
 PTSD and, 122–123
 roles in anxiety/fear, 2
 Amyotrophic lateral sclerosis (ALS), 343–344
 Anafranil (clomipramine), 122, 125–126, 171,
 220–221
 Anal stage, of child development (Freud), 34, 36
 Analysis of variance (ANOVA), 65
 Androgenic agent, for hypoactive sexual desire
 disorder, 137
 Angelman's syndrome, 285–286
 Angiotensin converting enzyme (ACE) inhibitors,
 264
 Anhedonia, in schizophrenia, 48, 105
 Anomia, 48
 Anorexia nervosa, 143–144
 medical treatment, 146
 Anosognosia, 48, 304
 Anterior capsulotomy, 281
 Anterior cerebral artery stroke, 304
 Anterior cingulotomy, 281
 Anticholinergics
 adverse effects, 268
 for impaired cognitive function, 77
 Anticonvulsants, 73, 154, 163–164, 282–283. *See*
 also carbamazepine; phenobarbital; pheny-
 toin; valproate
 Antidepressants. *See also* mirtazapine; selective
 serotonin reuptake inhibitors; tricyclic
 antidepressants (TCAs)
 adverse effects, 270
 amitriptyline, 171, 217–218
 amoxapine, 218–219
 for bipolar depression, 116–117. (*See also* bipolar
 disorders)
 for bulimia nervosa, 144–145
 bupropion (*See* bupropion)
 for children and adolescents, 171
 citalopram, 220
 clomipramine (*See* clomipramine)
 desipramine, 221
 desvenlafaxine, 222
 downregulation of postsynaptic β -adrenergic
 receptors from, 115
 doxepin, 222–223
 duloxetine, 223
 escitalopram, 224
 fluoxetine (*See* fluoxetine)
 fluvoxamine, 225
 for generalized anxiety disorder, 120
 heterocyclic antidepressants, 225
 imipramine, 171, 225–226
 isocarboxazid, 226
 maprotiline, 226–227
 mirtazapine, 11, 227
 nefazodone, 228
 norepinephrine, 115, 228
 nortriptyline, 171, 228–229
 paroxetine, 171, 229
 phenelzine, 229–230
 protriptyline, 230
 risks of withdrawal, 113
 selected serotonin receptors (*See* selective sero-
 tonin reuptake inhibitors (SSRIs))
 selegiline (transdermal), 230–231
 sertraline, 171, 231
 sexual dysfunction from, 141
 for social phobia, 122
 for Tourette's disorder, 179–180
 tranylcypromine, 232
 trazodone, 232–233
 trimipramine, 233
 venlafaxine, 141, 233–234
 Antiemetics, 73
 Antiepileptic drugs
 for antisocial personality disorder, 162
 causing renal stones, 298
 causing teratogenic defect, 298
 for herpes zoster, 293
 increasing seizure risks, 298
 inducing hepatic metabolism of oral
 contraceptives, 298
 not blocking Na⁺ channel, 298
 Antifungal medications, 263–264. *See also* ketocon-
 azole; miconazole
 Antilirium (physostigmine), 75, 268
 Antipsychotics, 264. *See also* atypical
 antipsychotics
 for acute agitation/oral vs. injections, 197
 adverse effects, 270, 271
 anticholinergic symptoms in, 268
 atypical vs. typical, 197
 for bipolar depression, 117
 for body dysmorphic disorder, 125–126
 for borderline personality disorder, 163–164
 for children and adolescents, 171
 glycine with, 104
 low vs. high potency agents, side effects, 207–208
 for PTSD, 123
 specific antipsychotics
 aripiprazole, 171
 chlorpromazine, 198
 clozapine (*See* clozapine)
 droperidol, 199–200
 fluphenazine, 200
 haloperidol, 200–201
 loxapine, 201–202

444 Index

- Antipsychotics (*Cont.*)
 molindone, 202
 olanzapine, 73, 202–203
 paliperidone vs. risperidone, 203
 perphenazine, 203–204
 pimozide, 204
 prochlorperazine, 204–205
 quetiapine, 75, 205
 risperidone, 73, 205–206
 thioridazine, 206
 thiothixene, 207
 trifluoperazine, 207
 ziprasidone, 208
 for Tourette's disorder, 179–180
 use in demented/elderly, 73
- Antiretroviral agents, 262
- Antisocial Personality Disorder, 83, 85–86, 164
 general background, 162
 ICD-10 vs. *DSM-IV-TR*, 166
 treatment for, 162
- Anton's syndrome, 48
- Anxiety disorders, 85–86
 acute stress disorder, 119
 adenosine receptor/panic disorder, 120
 agoraphobia, 120
 biofeedback for, 189
 from cocaine use, 92
 generalized anxiety disorder, treatment, 120
 from hallucinogens, 94
 mood disorders with, 112
 neurophysiology of, 120
 obsession vs. compulsion, 120–121
 obsessive compulsive disorder (OCD), 121
 panic attacks, 121
 panic disorders, 121–122
 phobias, 122
 posttraumatic stress disorder (*See* posttraumatic stress disorder)
 prevalence of, 124
 primary vs. organic anxiety syndrome, 124
- Anxiolytics and hypnotics
 alprazolam, 236
 benzodiazepines (*See* benzodiazepines)
 buspirone, 120, 122, 125–126, 237
 chloral hydrate, 237–238
 chlordiazepoxide, 238
 clonazepam, 154, 237, 238–239
 clorazepate, 239
 for conversion disorder, 126
 diazepam, 237, 239–240
 estazolam, 237, 240
 eszopiclone, 240
 flurazepam, 237, 240–241
 gamma-hydroxybutyrate (GHB), 91, 93, 152, 241–242
 hydroxyzine, 242
 lorazepam, 237, 242–243
 oxazepam, 237, 243
 ramelteon, 243–244
 temazepam, 244
 triazolam, 244
 zaleplon, 245–246
 zolpidem, 246
- Aphagia/dysphagia, 339
- Aphasias
 acquired receptive (epileptic) aphasia, 176
 conduction aphasia, 339
 fluent aphasia, 340
 global aphasia, 340–341
 non-fluent aphasia, 341
 paraphasias, 342
 transcortical aphasia, 342
- Apoptosis vs. necrosis, 19
- Apraxia, 48
- Arieti, Silvano, 115–116
- Aripiprazole, 197, 268, 271
 adverse effects, 272
 for children and adolescents, 171
- Arnold, Julius, 286
- Arnold-Chiari malformation, 286
- Arousal and wakefulness
 anatomy of, 19
 electrophysiology of, 20
- Arrhythmias, from cocaine, 91–92
- Artane (trihexyphenidyl), 275
- Asendin (amoxapine), 218–219
- Aspartate aminotransferase (AST), 85
- Asperger, Hans, 172
- Asperger's disorder, 172
- Aspirin, 266
- Assertiveness training, for dependent personality disorder, 164
- Astrocytoma, 312
- Ataque de nervios (culture bound syndrome), 373–374
- Ataxia/gait disturbances, 78, 88
- Atherosclerosis and Binswanger's disease, 73
- Athetosis, 333
- Ativan (lorazepam), 237, 242–243, 245
- Atomoxetine (Strattera), 257
- Attachment bond, 37
 biofeedback for, 189
 comorbid conditions, 177
 Multimodal Treatment Study of children with ADHD, 179
- Attribution theory, 37
- Atypical antipsychotics, 73
 adverse effects, 272, 275
 CYP450 interactions by, 263
 pregnancy safety of, 213–214
 typical vs., 197
- Audible thoughts (auditorization), 103–104
- Auditory system, 2–3
- Autistic disorders (Kanner's syndrome), 171, 173
- Aventyl (nortriptyline), 171, 228–229
- Avoidance learning, 43
- Avoidant attachment (of children), 27–28

- Avoidant personality disorder, 162
 dependent vs., 164–165
 ICD-10 vs. *DSM-IV-TR*, 166
- Avolition (poverty of activity), in schizophrenia, 105
- Axis I-V disorders (multiaxial system), 56
- Barbiturates, 13, 298
 ECT and, 282–283
 porphyria and, 181
 Wada test and, 63
- Barré, Jean-Alexandre, 346–347
- Basal ganglia
 child development and, 30
 functional neuroanatomy, 3
 nondeclarative memory and, 23
 in schizophrenia, 101
 serotonin and, 18
- Bateson, Gregory, 41
- Battered children, 360
- Beck, Aaron, 58
- Beck Depression Inventory (BDI), 58
- Becker's dystrophy, 344
- Behavioral therapy. *See also* cognitive behavior therapy (CBT); dialectical behavior therapy (DBT)
 for conversion disorder, 126
 for hypoactive sexual desire disorder, 137
 for OCD, 121
 for phobias, 122
- Benadryl (diphenhydramine), 269
- Bender, Lauretta, 58–59
- Bender gestalt test, 58–59
- Benzodiazepines, 13, 93–94, 262, 266. *See also* alprazolam; diazepam; estazolam; lorazepam; triazolam
 for borderline personality disorder, 163–164
 ECT and, 276, 279, 282–283
 general considerations, 236–237
 for generalized anxiety disorder, 120
 for impaired cognitive function, 77
 for insomnia, with delirium, 75
 with long half life, 237 (*See also* chlordiazepoxide; clonazepam; clorazepate; diazepam; flurazepam; halazepam; prazepam; quazepam)
 with medium to short half life, 237 (*See also* alprazolam; estazolam; lorazepam; oxazepam; temazepam; triazolam)
 for panic disorder, 122
 for phobias, 122
 for PTSD, 123
 quick onset of action, 243 (*See also* alprazolam; diazepam; estazolam; lorazepam; triazolam)
 for restless leg syndrome, 154
 short-term, for mania, 117
 sundowning and, 79
 use of, with liver impairment, 245 (*See also* lorazepam (Ativan); oxazepam; temazepam)
 withdrawal from, 245
- Benzphetamine (Didrex), 257–258
- Benztropine (Cogentin), 268
- Bertillon, Jacques, 55
- Bertillon Classification of Causes of Death. *See* International Statistical Classification of Diseases and Related Health Problems (ICD)
- Beta blockers, 162, 263–264. *See also* labetalol; propranolol
- Betrayal trauma, 131
- Bibring, Edward, 115–116
- Binge eating disorder, 144
- Binswanger, Otto, 73
- Binswanger's disease (subcortical arteriosclerotic encephalopathy), 73
- Bioethics (basics), 364. *See also* legal and ethical issues
- Biostatics
 analysis of variance (ANOVA), 65
 case controlled study, 65
 chi-square (χ^2), 65
 cohort study, 66
 confidence intervals, 66
 construct validity, 66
 correlation coefficient, 66
 dependent/independent variable, 66
 descriptive study, 67
 intervention study, 67
 kappa values, 67
 meta-analysis, 67
 null hypothesis (H_0), 67
 associated errors, 67
 p-value, 68
 positive predictive value/negative predictive value, 68
 prevalence vs. incidence, 68
 regression, 68
 regression analysis method, choice determination, 65–66
 relative risk vs. odds ratio, 68
 reliability, 69
 sensitivity vs. specificity, 69
 standard deviation (SD), 69
 standard error (SE) vs., 69–70
 validity (internal, external, construct), 70
- Bipolar disorders, 83, 107. *See also* anticonvulsants; antidepressants; antipsychotics; carbamazepine; lamotrigine; mood disorders
 ADHD with, 177
 in adolescents, 171
 cyclothymic disorder, 112
 ECT for, 116–117
 in elderly people, 111
 epidemiology of, 114
 genetics of, 114
 PTSD with, 123

446 Index

- Bipolar disorders (*Cont.*)
 with rapid cycling, 111
 treatment for, 116–117
- Black pitch delirium, 73
- Bleuler, Eugen, 102
- Body dysmorphic disorder
 hypochondriasis vs., 127
 taijin kyofusho vs., 382
 treatment, 125–126
- Borderline personality disorder
 alternative terminology, 163
 gender identity disorder vs., 137
 general information, 163
 ICD-10 vs. *DSM-IV-TR*, 166
 rapprochement and, 34
 treatment for, 163–164
- Botulinum toxin, 334, 344
- Bouffée délirante (culture bound syndrome), 374
- Bowlby, John, 27–28, 116
- BPRS. *See* brief psychotic rating scale (BPRS)
- Brain fag (culture bound syndrome), 374–375
- Brain fissures
 Rolandic fissure, 7
 Sylvian fissure, 7
- Brain tumors and injuries
 acute neuroma, 312
 astrocytoma, 312
 at cerebellopontine angle, 317
 coup/countercoup injuries, 313
 glioblastoma, 313
 hematomas
 epidural, 313
 subdural, 316
 meningiomas, 313, 314
 metastatic tumors, 314
 pituitary adenoma, 314
 postconcussion memory impairment, 315
 pseudotumor cerebri
 clinical features, 314
 diagnosis, 315
 risk factors, 315
 treatment, 315
 shaken baby syndrome, 315
 at temporal lobe, 317
 traumatic brain injury (pathological change),
 316–317
- Brief focal psychodynamic psychotherapy, 190
- Brief psychotherapy, 126, 190, 195
- Brief psychotic disorder, 101
- Brief psychotic rating scale (BPRS), 59
- Briquet, Paul, 126
- Briquet's syndrome, 126
- Bromocriptine (Parlodel), 154
- Brown-Sequard, Charles, 326
- Brown-Sequard syndrome, 326
- Bulbar vs. pseudobulbar palsy, 305
- Bulimia nervosa
 described, 144
 treatment for, 144–145
- Buprenorphine (Buprenex, Subutex, Suboxone),
 248–249
- Bupropion (Wellbutrin, Wellbutrin SR, Wellbutrin
 XL), 116–117, 262–263
 adverse effects, 270
 ECT interaction with, 279, 282–283
 general information, 219–220
 sexual dysfunction (possible) from, 141
- Buspirone (BuSpar)
 for body dysmorphic disorder, 125–126
 general information, 237
 for generalized anxiety disorder, 120
 for panic disorder, 122
- Caffeine, 82, 124, 264
 anxiety disorders and, 120
 mechanism of action, 90
- CAGE (alcohol screening) questionnaire, 85
- Calcium channel blockers, 263–264. *See also* dilti-
 azem; verapamil
- Campral (acamprosate), 16, 247–248
- Cannabis/cannabinoid receptors, 82, 83
 conjunctival infections from, 93, 99
 induced disorders, 90
 mechanism of action, 90
 specific signs/symptoms, 90
- Capgras, Joseph, 48
- Capgras syndrome, 48
- Carbamazepine, 264, 266
 adverse effects/safety caution, 210
 for bipolar disorder, 117
 causing teratogenic defect, 298
 general information, 209–210
 laboratory assessment, 210–211
 for partial seizures, 299
 pharmacokinetic interactions of, 262–263
 pregnancy safety of, 213–214
- Carbatrol. *See* carbamazepine
- Carbidopa/levodopa (Sinemet), 154
- Cardiac effects
 of cocaine, 91–92
 of inhalants, 95
- Carotid artery TIAs, 305
- Carpal tunnel syndrome
 clinical features, 344
 pathophysiology/treatment, 345
- Castration anxiety, 33, 34, 44
- Catalepsy, 48
- Cataplexy, 49
- Catatonia, in schizophrenia, 106–107
- Catecholamines, 11. *See also* dopamine; epineph-
 rine; norepinephrine
- Cathexis/acathexis, 49
- Cauda equina syndrome, 326
- Caudate nucleus, functional neuroanatomy, 3–4
- Celexa (citalopram), 220
- Centrex (prazepam), 237
- Cerebellar hemorrhage, 305
- Cerebellum function, 4

- Cerebral palsy (spastic), 287
- Cerebrospinal fluid
 appearance/related pathology, 293
 formation/absorption, 4
 glucose levels, 326
 suicide and, 356
 WBC counts, 293
- Cerebrovascular accidents, risk factors, 306
- Cerebrovascular effects, of cocaine, 91–92
- Cervicular radiculopathy, 328
- CGI. *See* clinical global improvement scale (CGI)
- Chantix (varenicline), 252
- Chi-square (χ^2) distribution, 65
- Chiari, Hans, 286
- Child abuse. *See also* incest
 battered children, 360
 parental characteristics, 360
 socioeconomic risks, 363
- Child and adolescent psychiatric disorders
 antipsychotics approved for, 171
 Asperger's disorder, 172
 comorbid conditions, 177
 Multimodal Treatment Study of children with
 ADHD, 179
 autistic disorder (Kanner's syndrome),
 173
 chronic motor/vocal tic disorder, 173
 conduct disorder, 174
 deceased parents/bereavement, 173
 depression (children), 174
 developmental coordination disorder, 174
 disintegrative disorder, 173
 Down's syndrome, 175, 179
 drug metabolism (children), 175
 DSM-IV-TR categories, 170–171
 encores, 175
 enuresis, 175
 expressive language disorder, 176
 fetal alcohol syndrome, 86, 176, 179
 Kleine-Levin syndrome, 176
 Landau-Kleffner syndrome, 176
 learning disorders, 176
 mental retardation
 common causes, 179
 diagnosis, 174–175
 functional level, 177
 pharmacologic agents for
 clonidine, 173–174
 psychostimulants, 177
 SSRIs, 171
 tricyclic antidepressants, 172
 phonological disorder, 177
 pica, 177
 reactive attachment disorder (infancy/early
 childhood), 178
 reading disorder, 178
 Rett's disorder, 178
 rumination disorder, 178
 selective mutism, 178
 separation anxiety disorder, 178
 stereotypic movement disorder, 179
 stuttering, 179
 Tourette's disorder, 179–180
 transient tic disorder, 180
 written expression disorder, 175
- Child development. *See also* adolescent
 development
 attachment styles, 27–28
 behavior-neurological maturation correlation,
 30
 behavioral milestones
 for 2 years old, 27–28
 for 3 years old, 29
 for 4 years old, 29
 for 5 years old, 29
 death, understanding permanency of, 35
 egocentrism (Piaget), 30
 Freud on, 29, 33, 34
 gender identity, 30
 gender role, 30
 good-enough mothering, 31
 imprinting, 31
 infantile amnesia, 31
 language milestones, 31–32
 object constancy, 32
 object relations theory, 32
 phallic stage, 33
 Piaget on
 concrete operational stage, 29
 developmental stages, 31
 egocentrism, 30
 object permanence, 32
 preoperational stage, 33
 preschool years, 29
 sensorimotor stage, 34
 rapprochement (reconciliation) stage, 34
 separation-individuation stages, 34
 social development model, 30
 stranger anxiety, 35, 46
 transitional object phase, 35
- Child neglect
 by parents, 362
 signs of, 362
- Chloral hydrate, 237–238
- Chlordiazepoxide (Librium), 237, 238
- Chlorpromazine, 198
- Chlorpromazine (Thorazine), 266, 378
- Cholinesterase inhibitors (class effects), 253
- Chorea, 49
- Cialis (tadalafil), 139–140, 265
- Cimetidine, 263–264, 266
- Cingulate gyrus, 7
 density reduction in schizophrenia, 106
 functional neuroanatomy, 4–5
 PTSD and, 122–123
- Ciprofloxacin, 263–264
- Circumstantiality/tangentiality, 49
- Citalopram (Celexa), 220

448 Index

- Classical conditioning (Pavlov)
 discrimination, 37
 extinction, 37–38
 generalization, 38
- Classification/diagnostic criteria
Diagnostic and Statistical Manual of Mental Disorders (DSM), 54–55
 specifiers in diagnosis, 56
- International Statistical Classification of Diseases and Related Health Problems (ICD), 55
 multiaxial system (Axis I–V), 56
 psychiatric diagnosis, validity of, 56
- Clerambault, syndrome, 50
- Clinical global improvement scale (CGI), 59
- Clomipramine (Anafranil)
 for body dysmorphic disorder, 125–126
 for children and adolescents, 171
 general information, 220–221
 for obsessive compulsive disorder, 121
 for panic disorder, 122
- Clonazepam (Klonopin), 154, 237
- Clonidine (Catapres), 154
 for children and adolescents, 173–174
 for substance-related disorders, 249
 for Tourette's disorder, 179–180
- Cloninger, Robert, 85
- Clorazepate (Tranxene), 237, 239
- Clozapine, 117
 adverse effects, 198–199, 268, 270, 271, 272
 clinical efficacy, 198
 ECT interaction with, 279, 282–283
 pharmacokinetic interactions of, 262–263
 WBC count/ANC monitoring, 199
- Clozapine for delirium, 75
- Club drugs, 91
- Cluster headaches
 clinical features, 319
 treatments, 319
- Cocaine, 82, 91
 cerebrovascular effects of, 91–92
 disorders induced by, 93
 use during pregnancy, 92
- Codeine, pharmacokinetic interactions, 263
- Cogentin (benztropine), 268
- Cognex (tacrine), 255
- Cognitive behavior therapy (CBT)
 for bipolar depression, 116–117
 for dependent personality disorder, 164
 for dissociative amnesia, 134
 for eating disorders, 147–148
 for generalized anxiety disorder, 120
 for panic disorder, 122
 for pedophilia, 139
 for phobias, 122
 for psychosocial disorders, 190, 191
 for PTSD, 123
 for Tourette's disorder, 179–180
- Cognitive disorders
 activities of daily living (ADL), 74
 aging, normal, 78
 Alzheimer's disease
 genetic findings, 72
 neuropathology, 72–73
 amnesia (etiology), 73
 antipsychotic use, in demented/elderly, 73
 Binswanger's disease, 73
 black pitch delirium, 73
 cognitive impairment, 74
 delirium
 clinical features, 74
 course and prognosis, 74
 epidemiology, 74–75
 proposed mechanisms, 75
 treatment, 75
 dementia
 epidemiology, 76
 frontotemporal, 78–79
 HIV-related, 76
 infectious etiology, 76
 laboratory workup, 76–77
 with Lewy bodies, 75–76
 mood disorders and, 77–78
 pharmacologic treatment, 78
 pugilistica, 77
 vascular, 77
 from electroconvulsive therapy, 276
 medicines associated with, 77
 normal pressure hydrocephalus (NPH), 78
 Pick's disease, 78–79
 Pittsburg compound B (PiB), 79
 sundowning, 79
 transient global amnesia, 80
- Cognitive dissonance, 38
- Cognitive enhancers and stimulants
 cholinesterase inhibitors (class effects), 253
 donepezil, 253–254
 galantamine, 254
 memantine, 254–255
 rivastigmine, 255
 tacrine, 255
- Cognitive therapy (Beck), 58
- Cohort studies, 66
- Compazine (prochlorperazine), 204–205
- Competency vs. capacity issue, 364–365
- Conduct disorder, 174
 ADHD with, 177
- Conduction aphasia, 339
- Confabulation, 49
- Confidence intervals, 66
- Confrontation intervention strategy, 190
- Confusion, 88
- Congenital adrenal hyperplasia (CAH), 137, 182
- Congenital neuropsychiatric disorders
 Angelman's syndrome, 285–286
 Arnold-Chiari malformation, 286

- cerebral palsy (spastic), 287
 cri-du-chat, 287
 Dandy-Walker syndrome, 287–288
 fragile X syndrome, 26, 179, 288, 290
 Klinefelter's syndrome, 137, 288
 mental retardation (associated with autosomal-recessive inheritance pattern), 288
 Prader-Willi syndrome, 286, 289
 Seckel syndrome, 289–290
 Sturge-Weber syndrome, 290
 triplet (trinucleotide) repeat expansion, 290
 Turner's syndrome, 291
 William's syndrome, 291
 Conjunctival infections, 93
 Construct validity, 60, 66, 70
 Conversion disorder, 126, 159
 Conversion therapy (reparative therapy), 193
 Coprolalia, 49
 Coprophilia, 138–139
 Correlation coefficient, 66
 Cotard's syndrome, 49
 Countertransference, 38, 194
 Coup/countercoup injuries, 313
 Creutzfeldt-Jakob disease, 184
 Cri-du-chat, 287
 Cryptococcus, 292
 Cullen, William, 51
 Cultural and social psychiatry. *See* culture bound syndromes
 Cultural determinism, 375
 Cultural formulation, 375–376
 Culture bound syndromes. *See also* National Alliance for the Mentally Ill (NAMI); National Institute of Mental Health Epidemiologic Catchment Area Survey (NIMH-ECA)
 altruism, 372
 amafufanyane, 372
 amok, 372–373
 Asian patients, 373
 ataque de nervios (attack of nerves), 373–374
 bilis and colera, 374
 bouffée délirante (acute delusional psychosis), 374
 brain fog, 374–375
 death in ethnic groups, 376
 dhat, 376
 domestic violence, 376
 downward drift hypothesis, 41, 376
 falling out/blacking out, 377
 gender and mental illness, 377
 ghost sickness, 378
 koro, 378
 latah, 378–379
 mal de ojo (evil eye), 379
 mental illness, prevalence in U.S., 380
 piblokto, 380
 prevention levels, 379
 psychiatric therapeutics (initial introductions), 378
 Shen-k'uei/shenkui, 381
 Shenjing shuairuo/neurasthenia, 381
 studies
 Chicago clinical study, 375
 midtown Manhattan (NYC), 379
 New Haven (Connecticut), 380
 susto (fright), 381
 taijin kyofusho (people phobia), 382
 twin studies
 IQ, 382
 personality/behavior patterns, 382
 zar, 382
 Cushing's syndrome, 107
 Cymbalta (duloxetine), 223, 270
 Cytomegalovirus (CMV) infections, 292–293
 Dalmane (flurazepam), 237
 Dandy, Walter, 287–288
 Dandy-Walker syndrome, 287–288
 Dantrium (dantrolene), 268–269
 Dantrolene (Dantrium), 268–269
 Date rape drugs, 93
 Death
 ECT and, 279
 reaction to approach, 192
 risks of
 from antipsychotics, 73
 from aripiprazole, 197
 from chlorpromazine, 198
 from clozapine, 198
 from fluphenazine, 200
 from haloperidol, 201
 from loxapine, 201
 from molindone, 202
 from olanzapine, 202
 from perphenazine, 203
 from pimozide, 204
 from prochlorperazine, 205
 from quetiapine, 205
 from risperidone, 206
 from thioridazine, 206
 from thiothixene, 207
 from ziprasidone, 208
 sudden
 from cocaine, 92
 from PE5 inhibitors, 139–140
 understanding permanency of (children), 35
 Declarative (explicit) memory, 22
 Deep brain stimulation (DBS)
 adverse effects/potential complications, 277
 indications for, 277
 Defense mechanisms
 acting out, 38
 altruism, 38
 blocking, 38
 controlling, 38
 denial, 39

450 Index

- Defense mechanisms (*Cont.*)
 devaluation, 39
 displacement, 39
 introjection, 39
 isolation, 40
 passive aggression, 40
 projection, 40
 projective identification, 40
 rationalization, 40
 reaction formation, 40
 regression, 40
 repression, 40
 somatization, 40
 splitting, 41
 sublimation, 41
 suppression, 41
 undoing, 41
- Defensive functioning scale (DFS), 59
- Déjà pense, 49
- Déjà vu, 49
- Delirium, 74
 clinical features, 74
 from cocaine use, 92
 course and prognosis, 74
 epidemiology, 74–75
 from hallucinogens, 94
 proposed mechanisms, 75
 treatment, 75
- Delsym (dextromethorphan), 264
- Delusional disorder, 101–102
 hypochondriasis vs., 127
- Delusional perceptions, 103–104, 106–107
- Delusions, 101–102. *See also* Bouffée délirante
 in Capgras syndrome, 48
 in Cotard's syndrome, 49
 in dementia with Lewy bodies, 75–76
 in erotomania, 50
 in Folie à deux, 50
 in gender identity disorder, 137
 in idiosyncratic alcohol intoxication, 86
 in nihilism, 52
 in paraphrenia, 106
 in schizophrenia, 102, 104
 from sensory deprivation, 45
- Dementia, 21, 74. *See also* Alzheimer's disease;
 amnesia; pseudodementia
 epidemiology, 76
 frontotemporal dementia, 78–79
 HIV-related, 76, 293–294, 365
 infectious etiology, 76
 laboratory workup, 76–77
 with Lewy bodies, 75–76
 mood disorders and, 77–78
 NPH and, 78
 pharmacologic treatment, 78
 pugilistica, 77
 vascular, 77
- Dementia precox. *See* schizophrenia
- Demyelination, 24–25
- Dependent/independent variables, 66
- Dependent personality disorder, 164
- Depersonalization disorder, 132
- Depression, 21, 83, 85–86. *See also* antidepressants;
 mood disorders; postpartum depression
 ADHD with, 177
 assessment tools
 Beck Depression Inventory, 58
 Hamilton Rating Scale for Depression, 61
 Zung Self-Rating Depression Scale, 64
 atypical, 111
 in children, 174
 dexamethasone suppression test, 113
 double depression, 113
 duration of episodes, 113
 in elderly people, 112
 endocrinological changes in, 113
 major depressive disorder, 83, 85–86
 epidemiology of, 114
 OCD and, 121
 MAOIs for, 111, 116–117
 not otherwise specified, 112
 psychodynamic view of, 115–116
 PTSD with, 123
 sleep disorders in, 116, 151
 treatments, 117
- Dermatomes, 329
- Desipramine (Norpramin), 221
- Desoxyn (methamphetamine), 91, 95, 259–260
- Desvenlafaxine (Pristiq), 222
- Desyrel (trazodone), 232–233
- Developmental articulation disorder (phonological
 disorder), 177
- Developmental coordination disorder, 174
- Dexamethasone suppression test (DST), 113
- Dextroamphetamines (Dexedrine), 258
- Dextromethorphan (Delsym, Silphen DM,
 Robitussin DM), 264
- DFS. *See* defensive functioning scale (DFS)
- Dhat (culture bound syndrome), 376
- Diabetes, maternal, 106
- Diagnostic and Statistical Manual of Mental
 Disorders (DSM)*. *See also* Mini-
 International Neuropsychiatric Interview
 (MINI); Social and Occupational
 Functioning Assessment Scale (SOFAS);
 Structured Clinical Interview for the
 DSM-IV (SCID)
- I (1952), 54
 II and III (1968), 54
 III (1980), 54–55
 III-R (1987), 54–55
 IV (1994), 55
 specifiers in diagnosis, 56
- Diagnostic and Statistical Manual of Mental
 Disorders (DSM) IV-TR (2000)*, 55
 anxiety disorders, 119
 child and adolescent disorders, 170–171
 dissociative disorders, 131

- eating disorders, 143
 factitious disorders, 157
 mood disorders, 110
 personality disorders, 161–162
 psychosomatic disorders, 181
 psychotic disorders, 100
 sexual and gender identity disorders, 135–136
 somatoform disorders, 125
 substance-related disorders, 81
 dependence but not abuse, 82
 no withdrawal diagnosis, 82
 other than alcohol, 89
- Dialectical behavior therapy (DBT). *See also*
 mindfulness
 for borderline personality disorder, 163–164
 mindfulness and, 192
 for psychosocial disorders, 190–191
- Diazepam (Valium), 237, 239–240
- Didrex (benzphetamine), 257–258
- Diltiazem, 263–264
- Diphenhydramine (Benadryl), 269
- Diplopia, 93, 99
- Direct-coupled ion channels, 11–12
- Discontinuation syndromes, 269–270
- Disintegrative disorder (in childhood), 173
- Disorganized attachment (of children), 27–28
- Dissociative disorders
 betrayal trauma, 131
 central concepts of, 133
 depersonalization disorder, 132
 dissociative amnesia, 132
 treatments for, 134
 dissociative fugue, 132
 dissociative identity disorder, 132
 etiology (proposed) of, 132–133
 ICD-10 vs. *DSM-IV-TR*, 166
 malingering vs., 159
 neurological research on, 133
 recovered memory syndrome, 133
- Disulfiram (Antabuse), 249–250
- DMT (dimethyltryptamine), 93–94
- Dolophine (methadone), 250–251
- Domestic violence, risk factors for abusers/victims,
 361, 376
- Dominant other concept (Arieti), 115–116
- Donepezil (Aricept), 253–254
- Dopamine. *See also* reward system
 caffeine enhancement of, 90
 nuclei (localization), 12
 receptors, 12
 reuptake blocking by cocaine, 82
 schizophrenia and
 dopamine hypothesis, 102
 type 2 receptors, 103
 substantia nigra production of, 9
 synthesis (mechanism), 12
 tracts/physiological function, 13
 VTA activation of, 2, 9
- Dopaminergic agents, for restless leg syndrome,
 154
- Doral (quazepam), 237
- Double bind syndrome, 41
- Double depression, 113
- Down's syndrome, 175
- Downward drift hypothesis, 41, 376
- Doxepin (Sinequan), 222–223
- Draw-A-Person test, 59–60
- Dreams
 from alcohol, 150
 in amphetamine/cocaine intoxication and with-
 drawal, 89–90
 in ghost sickness, 378
 methods of disguise (Freud), 42
 psychoanalytic interpretation, 41–42
 in REM/NREM periods, 151
 in susto, 381
- Droperidol (Inapsine), 199–200, 266
- DSM. See Diagnostic and Statistical Manual of
 Mental Disorders*
- Duchenne's muscular dystrophy, 346
- Duloxetine (Cymbalta), 223, 270
- Durkheim, Emile, 357
- Dysphagia, 339
- Dysprosody, 50
- Dysthymia, 83
- Dystonia, 333
 dopa-responsive, 334
 early onset primary, 334
- Eating disorders and weight issues
 adipocytes, developmental traits of, 145
 anorexia nervosa, 143–144
 medical treatment, 146
 binge eating, 144
 bulimia nervosa
 clinical features, 144
 pharmacological treatment, 144–145
 DSM-IV-TR categories, 143
 epidemiology of, 145
 fat distribution, 145
 ipecac syrup (abuse of), 145–146
 laboratory changes in, 146
 leptin (regulatory fatty tissue hormone), 146
 Orlistat (OTC medication), 146–147
 Pickwickian syndrome, 147
 psychiatric eating disorders, 147–148
 test recommendations, 148
- Eaton, Lealdes, 346
- Eaton-Lambert syndrome, 346
- Ecstasy (MDMA). *See* methylenedioxymetham-
 phetamine (MDMA)
- ECT. *See* electroconvulsive therapy (ECT)
- Efavirenz, 262
- Ego psychology, 42
- Eidetic images, 50
- Elavil (amitriptyline), 171, 217–218
- Electra complex, 44

452 Index

- Electroconvulsive therapy (ECT). *See also* deep brain stimulation; psychosurgery; transcranial magnetic stimulation (TMS)/repetitive TMS; vagus nerve stimulation
 adverse effects/risks, 281–282
 for bipolar depression, 116–117
 cognitive impairment in, 276
 conditions leading to consideration for, 277
 contraindications for, 277
 for delirium, 75
 electrical factors/electrode placement, 278
 indications for, 278
 introduction (1938), 378
 for manic/mixed episodes, 117
 mechanism of, 279
 mortality of, 279
 for postpartum depression, 115
 pregnancy and, 280
 psychotropic medication interaction with, 279
 seizure quality in, 281
 seizure threshold in, 282–283
 structural brain damage and, 283
 succinylcholine's adverse effects during, 279
- EMDR. *See* eye movement desensitization and reprocessing (EMDR)
- EMSAM (transdermal selegiline), 230–231
- Encephalitis, from CMV, 292–293
- Encores, 175
- Enmeshment vs. disengagement, 191
- Enuresis, 175
 nocturnal enuresis, 172
- Epidural hematomas, 313
- Epilepsy, 25. *See also* antiepileptic drugs
 absence seizures, 298, 299
 drugs (first-line) for, 299, 301
 epidemiology of, 299
 frontal lobe partial seizures, 299
 grand mal seizures, 300
 occipital lobe partial seizures, 301
 parietal lobe partial seizures, 301
 personality changes from, 301
 pregabalin for, 301–302
 pregnancy and, 299
 suicide and, 302
 surgical treatment for suicide and, 303
 temporal lobe focal seizures, 303
- Epinephrine, 11
- Epitol. *See* carbamazepine
- Epstein-Barr virus infection, 292
- Equetro. *See* carbamazepine
- Ergotamine for headaches, 319, 320, 322
- Erikson, Erik, 27
 on preschool years, 29
 social development model, 30
- Erotomania (Clerambault syndrome), 50
- Erythromycin, 263–264
- Escape learning, 43
- Escitalopram (Lexapro), 224
- Eskalith/Eskalith CR. *See* lithium
- Estazolam (ProSom), 237, 240
- Eszopiclone (Lunesta), 240
- Ethical issues. *See* legal and ethical issues
- Ethosuximide, for absence seizure, 298, 299
- Evaluation of signs and symptoms
 abulia, 47
 acathexis/cathexis, 49
 acrophobia, 47
 affect vs. mood, 47
 agnosia, 47
 agraphia, 47
 akathisia, 47
 akinesia, 47
 alexithymia, 48
 amaurosis fugax, 48
 anhedonia, 48
 anomia, 48
 anosognosia, 48
 Anton's syndrome, 48
 apraxia, 48
 Capgras syndrome, 48
 catalepsy, 48
 cataplexy, 49
 cathexis/acathexis, 49
 chorea, 49
 circumstantiality/tangentiality, 49
 confabulation, 49
 coprolalia, 49
 Cotard's syndrome, 49
 déjà pense, 49
 déjà vu, 49
 dysprosody, 50
 eidetic images, 50
 erotomania (Clerambault syndrome), 50
 executive function, 50
 Folie à deux, 50
 formication, 50
 hallucinations, hypnagogic/hypnopompic, 51
 hyperacusis, 50
 infantile amnesia, 51
 jamais vu, 51
 la belle indifférence, 51
 lethologica, 51
 neologism, 51
 neurosis, 51
 paramnesia, 52
 passive aggression, 52
 peduncular hallucinosis, 52
 perseveration, 52
 precoc feeling, 52
 synesthesia, 52
 thought blocking, 53
 trismus, 53
 verbigeration, 53
- Evoked potential (EP), 20–21
- Excitatory neurotransmitters, 15
- Excitotoxicity, 21
- Executive function, 50, 74
 deep brain stimulation (DBS) and, 277

- prefrontal cortex and, 172
 Wisconsin Card Sorting test evaluation, 63
- Exelon/Exelon Patch (rivastigmine), 255
- Explicit (declarative) memory, 22
- Expressive language disorder, 176
- Expressive psychotherapy, 192
- External validity, 70
- Eye movement desensitization and reprocessing (EMDR), 123
- Eye/vision specific symptoms. *See also* Veraguth's fold
 glaucoma, from antidepressants, 270
 from non-alcohol addictions, 93, 94
 nystagmus, 88, 93
 smooth pursuit eye movements, 108
- Facial dysmorphisms, 86
- Factitious disorders. *See also* malingering
 clinical features, 157
 defense mechanisms, 157
 DSM-IV-TR categories, 157
 Ganser's syndrome, 158
 hallucinations (real vs. faked), 158
 Munchausen syndrome, 160
 treatment principles, 158
- Femoral nerve injury, 346
- Festinger, Leon, 38
- Fetal alcohol syndrome, 86, 176, 179
- Finger agnosia, 340
- 5HT₃ (direct-coupled ion channel receptor), 11–12, 86
- Flashbacks (persistent perception disorder), 94
- Flat (emotional) affect, 105
- Fluent aphasia
 clinical characteristics, 340
 pathology, 340
- Flumazenil (Romazicon), 250
- Flunitrazepam (Rohypnol), 91, 93
- Fluoxetine (Prozac), 264
 for bulimia nervosa, 144–145
 for children and adolescents, 171
 general information, 224–225
 introduction (1987), 378
- Fluphenazine, 200
- Flurazepam (Dalmane), 237, 240–241
- Fluvoxamine (Luvox, Luvox CR), 225
- Folie à deux, 50
- Folie à deux (Shared Psychotic Disorder), 50
- Formication, 50
- Fragile X syndrome, 26, 179, 288, 290
- Free association, 191
- Freeman, Walter, 280–281
- Freud, Sigmund, 27. *See also* castration anxiety;
 Oedipus complex; penis envy; resistance
 on anal stage, of child development, 34, 36
 on cultural determinism, 375
 on dreams/methods of disguise, 42
 on phallic stage of child development, 33
 on preschool years, 29
 psychoanalytical psychotherapy and, 192
- schizophrenia formulation by, 104
 suicide theory, 359
- Freyd, Jennifer, 131
- Friedman, Meyer, 46
- Frontotemporal dementia, 78–79
- Functional neuroanatomy
 amygdala, 7
 anatomy of, 2
 roles in anxiety/fear, 2
- auditory system, 2–3
 basal ganglia, 3
 brain fissures, 7
 caudate nucleus, 3–4
 cerebellum (function), 4
 cerebrospinal fluid, 4
 cingulate gyrus, 4–5, 7
 glial cells, 5
 globus pallidus, 5, 8
 Heschl's gyrus, 6
 hippocampus, 6, 7
 hypothalamus, 6, 7, 8
 limbic system, 7
 nucleus accumbens, 8, 9
 prefrontal cortex, 8
 primary sensory cortex, 8
 putamen, 8
 reticular formation, 8–9
 reward system, 9
 striatum, 9
 substantia nigra, 9
 ventral tegmental area (VTA), 2, 9
- G-protein coupled receptors, 14
- Gait disturbance/ataxia, 78
- Galantamine (Razadyne, Razadyne ER), 254
- Gamma-aminobutyric acid (GABA)
 anxiety disorders and, 120
 inhalant enhancement, 95
 receptors, 13, 86 (*See also* barbiturates;
 benzodiazepines)
 in schizophrenia pathology, 104
 synthesis, 13 (*See also* glutamate)
- Gamma-glutamyl transpeptidase (GGT), 85, 86
- Gamma-hydroxybutyrate (GHB)(Xyrem), 91, 93
 general information, 241–242
 for NREM sleep, 152
- Ganser, Sigbert, 158
- Ganser's syndrome, 158
- Geese study (of imprinting), 31
- Generalized anxiety disorder, 83
 duloxetine for, 223
 escitalopram for, 224
 lifetime prevalence of, 124
 paroxetine for, 229
 treatment, 120
 venlafaxine for, 233–234
- Genetics
 of bipolar disorders, 114
 of schizophrenia, 104

454 Index

- Geodon (ziprasidone), 208, 266, 268, 271, 272
 Gerstmann, Josef, 340
 Gerstmann's syndrome, 340
 Gestalt psychology, 58–59
 Ghost sickness (culture bound syndrome), 378
 Gilligan, Carol, 43
 Glaucoma, from antidepressants, 270
 Glial cells, functional neuroanatomy, 5
 Glioblastoma, 313
 Global aphasia, 340–341
 Global assessment of functioning (GAF), 60
 Global assessment of relational functioning (GARF), 60
 Globus pallidus, 5, 8
 Glutamate
 depersonalization disorder and, 133
 GABA synthesis precursor, 13
 receptors, 11–12. *See also* NMDA glutamate receptor
 excitotoxicity and, 21
 schizophrenia and, 104
 as VTA component, 9
 Glutamic acid decarboxylase (GAD), 13
 Glycine, 13, 15, 16
 for schizophrenia, 104
 tetanus interference with, 349
 Good-enough mothering (Winnicott), 31
 Grandma's rule (Premack's principle), 45
 Group therapy
 for dependent personality disorder, 164
 for eating disorders, 147
 for pedophilia, 139
 for rape, 353
 Guaifenesin (Robitussin), 264
 Guanfacine, for Tourette's disorder, 179–180
 Guillain, Georges, 346
 Guillain-Barré syndrome, 293, 346–347
 Guze, Samuel, 56
- Halazepam (Paxipam), 237
 Halcion (triazolam), 244
 Hallucinations, hypnagogic/hypnopompic, 51
 real vs. faked, 158
 in schizophrenia, 102, 106–107
 non-first-rank, 103–104
 Hallucinogens, 93–94
 disorders induced by, 94
 intoxication, signs/symptoms, 94
 Haloperidol (Haldol), 75, 200–201, 262–263
 Halstead, Ward, 60
 Halstead-Reitan neuropsychological battery, 60
 Hamilton, Max, 61
 Hamilton Rating Scale for Depression (HAM-D), 61
 Headaches
 cluster headaches
 clinical features, 319
 treatments, 319
 demographics of, 319–320
 ergotamine for, 319, 320, 322
 from lesion occupying cranial space, 320
 with meningitis, 321
 migraines
 with aura, 321
 hemiplegic, 321
 pathophysiology of, 322
 status migrainous, 322
 treatment, 322
 without aura, 322
 provoking factors, 322–323
 pseudotumor cerebri, 323
 secondary, neuroimaging for, 323
 from subarachnoid hemorrhage, 320
 temporal arteritis, 323
 tension headache, 323–324
 trigeminal neuralgia
 clinical features, 324
 pathology, 324–325
 treatment, 325
 triptans for, 325
 Hebb, Donald, 45
 Hematomas, 313, 316
 Hemiballismus, 335
 Hepatic encephalopathy, 26
 Heschl, Richard, 342
 Heschl's gyrus, 6
 Heterocyclic antidepressants, 225
 Heterotopia, 25
 HIPAA privacy and security rule, 368
 Hippocampus, 6, 7
 memory and
 amnesia, 73
 declarative, 22
 formation/storage, 22–23
 PTSD and, 122–123
 schizophrenia and, 104
 Histamine, 11
 blockade (clinical effects), 14
 mirtazapine and, 227
 modafinil and, 152
 Histamine headaches, 319
 Histrionic personality disorder, 164, 165–166
 HIV-related disorders
 dementia, 76, 293–294, 365
 meningitis, 294
 serum test, 294
 Horizontal nystagmus, 88
 Hospitalization, involuntary, 366
 HPA. *See* hypothalamic-pituitary-adrenal axis (HPA)
 Huntington's disease, 26, 290, 335
 Hurler's syndrome, 288
 Hydroxyzine (Atarax, Vistaril), 242
 Hyperacusis, 50, 99
 Hypertension
 Binswanger's disease and, 73
 biofeedback therapy for, 189
 clonidine for, 173–174, 249
 dementia and, 77

- idiopathic intracranial hypertension (IIH), 314, 323
- intracranial hemorrhage from, 306–307
- MAOIs and, 270
- phencyclidine (PCP) and, 98–99
- propranolol for, 271–272
- sexual arousal disorder and, 140
- Hypnagogic/hypnopompic hallucinations, 51
- Hypnosis, 36
- for conversion disorder, 126
- for dissociative disorders, 134
- for dissociative fugue, 132
- Hypnotics. *See* anxiolytics and hypnotics
- Hypoactive sexual desire disorder, 137
- Hypochondriasis
- body dysmorphic disorder vs., 127
- course/prognosis, 126–127
- delusional disorder vs., 127
- diagnosis, 127
- epidemiology, 127
- etiology (theories), 127–128
- somatization disorder vs., 129
- Hypoglycemia
- alcohol withdrawal and, 84–85
- eating disorders and, 146
- functional pituitary adenoma and, 184–185
- neuropsychiatric symptoms, 186
- Hypomagnesaemia, 84–85
- Hyponatremia, 84–85
- Hypothalamic-pituitary-adrenal axis (HPA)
- child development and, 30
- dexamethasone suppression test and, 113
- mental disorders and, 21
- PTSD and, 122–123
- Hypothalamus, 6, 7, 8
- activation of SNS, 2
- child development and, 30
- melatonin and, 15
- Hypoxyphilia, 138
- Ibuprofen, 264, 266
- ICD. *See* International Statistical Classification of Diseases and Related Health Problems (ICD)
- Idiosyncratic alcohol intoxication, 86
- Imipramine (Tofranil, Tofranil PM)
- general information, 225–226
- introduction (1957), 378
- for panic disorder, 122
- Imprinting (phase-sensitive learning), 31
- Inapsine (droperidol), 199–200, 266
- Incest
- relations, 361
- socioeconomic consideration, 361
- Indinavir, 262
- Indomethacin, 264
- Infantile amnesia, 31, 51
- Inflammatory polyradiculoneuropathy, 346–347
- Informed consent issue, 366
- Inhalants, 94
- acting mechanisms, 95
- diplopia from intoxication, 99
- pathological effects, 95
- Inhibitory neurotransmitters, 13, 15
- Insight-oriented therapy
- for conversion disorder, 126
- for generalized anxiety disorder, 120
- Instrumental (operant) conditioning, 44
- Intelligence quotient (IQ)
- mental retardation diagnosis, 174–175
- Internal validity, 70
- International Statistical Classification of Diseases and Related Health Problems (ICD), 55
- version 10, vs. *DSM-IV-TR* for personality disorders, 166
- Internuclear ophthalmoplegia, 306
- Interpersonal psychotherapy, 192
- Intervention studies, 67
- Intoxication
- from amphetamines/cocaine, 89–90
- from cannabis, 99
- from hallucinogens, 94
- from inhalants, 99
- from lithium, 212
- from opioids, 97–98, 99
- from PCP, 99
- from phencyclidine (PCP), 99
- signs/symptoms, 98–99
- treatment, 99
- Intracranial hemorrhage, 306–307
- Invega (paliperidone), 203, 268, 272
- Involuntary hospitalization, 366
- Ipecac syrup (abuse of), 145–146
- IQ. *See* intelligence quotient (IQ)
- Irresistible impulse, 366
- Isocarboxazid (Marplan), 226
- Jamais vu, 51
- John Cunningham (JC) virus, 295–296
- Jung, Carl, 44, 51, 63
- Kanner's syndrome (autistic disorder), 173
- Kardiner, Abraham, 375
- Kegel, Arnold, 138
- Kernberg, Otto, 32
- Ketamine, 91, 93
- Ketoconazole, 263–264
- Klein, Melanie, 32, 40, 115–116
- Kleine-Levin syndrome, 176
- Klinefelter, Harry, 137
- Klinefelter's syndrome, 137, 288
- Klismaphilia, 138–139
- Klonopin (clonazepam), 154, 237
- Kohlberg, Lawrence, 43
- Kohut, Heinz, 44, 116
- Koro (culture bound syndrome), 378
- Korsakoff's syndrome, 88

456 Index

- Kraepelin, Emil, 72–73, 102
 Kubler-Ross, Elisabeth, 192
- La belle indifference, 51, 126
 Labetalol, 263–264
 Lacrimation (excessive tearing), 93, 99
 Lambert, Edward, 346
 Lambert-Eaton myasthenic syndrome (LEMS), 346
 Lamotrigine (Lamictal), 262–263, 266
 for bipolar disorder, 116–117
 general information, 211
 pharmacokinetic interactions, 264
 pregnancy safety of, 213–214
 Landau-Kleffner syndrome, 176
 Language impairments
 alexia without agraphia, 339
 aphagia/dysphagia, 339
 conduction aphasia, 339
 fluent aphasia
 clinical characteristics, 340
 pathology, 340
 formal language testing, 340
 Gerstmann's syndrome, 340
 global aphasia, 340–341
 language forms/relevant hemisphere, 341
 non-fluent aphasia
 clinical characteristics, 341
 pathology, 342
 paraphasias, 342
 pathways of language, 342
 transcortical aphasia, 342
 Language milestones (child development), 31–32
 Latah (culture bound syndrome), 378–379
 Late-onset schizophrenia, 105
 Lateral spinothalamic tracts, 329–330
 Learned helplessness (Seligman), 43
 Learning difficulties/disorders, 25, 86, 121
 Legal and ethical issues
 bioethics (basics), 364
 competency vs. capacity, 364–365
 confidentiality
 about HIV infection, 365
 in the court, 365
 confidentiality breaches, 364
 four (4) Ds in malpractice, 365
 guilty but mentally ill, 366
 HIPAA privacy and security rule, 368
 informed consent, 366
 involuntary hospitalization, 366
 irresistible impulse, 366
 justification of medical research randomization,
 365
 malpractice cases, standard of care, 369
 M'Naghten rule, 366
 negligent prescription practices, 367
 not guilty due to insanity, 367
 O'Connor vs. Donaldson, 367
 physician-assisted suicide, 367–368
 professional boundaries, 368
 reporting duties, 368
 seclusion and restraint, 369
 seductive patient management, 366–367
 statutory rape, 369
 Tarasoff I and II, 369
 workmen's compensation, 370
 Lennox, William, 300
 Lennox-Gastaut syndrome, 300
 Lethologica, 51
 Leukopenia, from antipsychotics, 270
 Levitra (vardenafil), 139–140, 265
 Lexapro (escitalopram), 224
 Librium (chlordiazepoxide), 237
 Limbic leucotomy, 281
 Limbic system, 7
 changes in schizophrenia, 105
 child development and, 30
 nondeclarative memory and, 23
 serotonin and, 18
 Lisdexamfetamine (Vyvanse), 259
 Lithium
 for bipolar disorder, 116–117
 for body dysmorphic disorder, 125–126
 ECT interaction with, 279, 282–283
 general information, 211–212
 intoxication from, 212
 introduction (1938), 378
 pharmacokinetics of, 212, 264
 polyuria/polydipsia induced by, 212–213
 pregnancy safety of, 213–214
 side effects (in mental status), 213
 Locked-in syndrome, 307
 Locus coeruleus, norepinephrine activation, 2, 120,
 122–123
 Lorazepam (Ativan), 237, 242–243, 245
 Lorenz, Konrad, 31
 Loxapine (Loxitane), 201–202
 LSD (lysergic acid diethylamide), 82, 91, 93–94, 95
 Ludiomil (maprotiline), 226–227
 Lumbo-sacral radiculoplexopathy, from encephalitis,
 292–293
 Lunesta (eszopiclone), 240
 Luvox/Luvox CR (fluvoxamine), 225
 Lyme disease, 294
 Lymphoma (central nervous system), 292
- Machado-Joseph disease, 26, 290
 Mahler, Margaret, 32, 34
 Major depressive disorder, 83, 85–86
 epidemiology of, 114
 OCD and, 121
 Mal de ojo (culture bound syndrome), 379
 Malan, David, 195
 Malignant Hyperthermia Association of the United
 States (MHAUS), 268–269
 Malingering
 assessment of, 159
 differential diagnoses, 159
 psychiatric management, 159–160

- Malinowski, Bronislaw, 375
 Malpractice cases, standards of care in, 369
 Mammillary body, 7, 73
 Mania. *See also* bipolar disorders; erotomania; nymphomania
 brain imaging studies, 112
 carbamazepine for, 209–210
 described, 114
 ECT for, 277, 281–282
 lamotrigine for, 211
 psychodynamic factors, 116
 right frontal lobe lesions and, 309
 treatment for, 117
 valproate for, 214–215
 Maprotiline (Ludiomil), 226–227
 ECT interaction with, 279, 282–283
 Marijuana, 83
 depersonalization from, 133
 Marplan (isocarboxazid), 226
 Masochism and sadism, 141
 Mead, Margaret, 375
 Melatonin, 15, 151–152
 Mellaril (thioridazine), 206, 266
 Memantine (Namenda), 16, 254–255
 Memory. *See also* Alzheimer's disease; amnesia; dementia; dissociative disorders; executive function
 abreaction process, 36
 declarative, 22
 ECT and loss of, 276
 formation and storage, 22–23
 infantile amnesia, 31
 long-term vs. short-term, 24
 nondeclarative, 23
 postconcussion impairment, 315
 priming (implicit/non-declarative memory), 45
 recovered memory syndrome, 133
 short vs. long-term, 24
 working, 24
 Meningiomas, 313, 314
 Meningitis
 causes, 294–295
 headaches with, 321
 HIV-related, 294
 subacute/chronic, 295
 Meningocele/meningomyelocele, 331
 Menninger, Karl, 359
 Meridia (sibutramine), 261
 Mescaline, 93–94
 Mesocortical dopamine pathway
 (reward system), 9
 Mesolimbic dopamine pathway (reward system), 9, 13
 Meta-analysis (statistic method), 67
 Metabolic encephalopathies, 26
 Methadone (Dolophine, Methadose), 250–251, 262
 Methamphetamines, 91, 95, 259–260
 Methylendioxyamphetamine (MDMA), 82, 91, 93–94, 95–96
 Methylphenidate (Concerta, Daytrana, Metadate, Ritalin), 125–126, 260
 for body dysmorphic disorder, 125–126
 Meyer, Adolf, 108
 Meynert, Theodor, 10
 Miconazole, 263–264
 Micro-/macrocephaly, 86
 Middle cerebral artery stroke, 308
 Migraine headaches
 with aura, 321
 from cocaine, 91–92
 hemiplegic, 321
 pathophysiology of, 322
 status migrainous, 322
 treatment, 322
 without aura, 322
 Millon, Theodore, 61
 Millon Clinical Multiaxial Inventory (MCMI), 61
 Mindfulness, 191, 192
 Mini-International Neuropsychiatric Interview (MINI), 61
 Minnesota Multiphasic Personality Inventory (MMPI), 61
 Minor depressive disorder, 112
 Minuchin, Salvador, 191, 193
 Mirtazapine (Remeron/Remeron SolTab), 11, 227, 270
 Mitochondrial respiratory chain diseases, 347
 Moban (molindone), 202
 Modafinil (Provigil)
 for narcolepsy, 152
 for NREM sleep, 152
 Molindone (Moban), 202
 Moniz, Egas, 280–281
 Monoamine oxidase inhibitors (MAOIs), 15
 adverse effects, 270–271 (*See also* serotonin syndrome)
 for body dysmorphic disorder, 125–126
 for depression, 111, 116–117
 ECT interaction with, 279
 and over the counter medications, 264
 for panic disorder, 122
 and serotonin elevating agents, 264–265
 sexual dysfunction from, 141
 Mood disorders, 21
 bipolar disorders (*See* bipolar disorders)
 brain imaging studies in, 112
 from cocaine use, 92
 comorbidities in, 112
 depression (*See* depression)
 DSM IV-TR categories, 110
 dysthymic disorder, 113
 mania (*See* mania)
 norepinephrine in, 115
 postpartum blues, 115
 postpartum depression, 115
 pseudodementia, 115
 serotonin in, 116
 Veraguth's fold, 118

458 Index

- Mood stabilizing medications. *See* carbamazepine; lamotrigine; lithium; oxcarbazepine; topiramate; valproic acid
- Moral development concept (Kohlberg), 43
- Morphine, 96, 262, 263
- Movement disorders
- athetosis, pathology of, 333
 - botulinum toxin, 334
 - clinical features, 338
 - diagnosis, 338
 - dystonia, 333
 - dopa-responsive, 334
 - early onset primary, 334
 - extrapyramidal system, 334
 - hemiballismus, 335
 - Huntington's disease, 335
 - Parkinson's disease
 - dementia with Lewy body vs., 75–76, 334
 - etiology, 335–336
 - pathology, 336
 - symptoms, 336
 - treatment, 336
 - pathophysiology, 338
 - pyramidal system, 336
 - Sydenham's chorea, 336–337
 - treatment, 338
 - trinucleotide repeats, illness with expansion of, 335
 - with vs. without dementia, 335
 - Wilson's disease, 338
- Multiaxial system (Axis I-V), 56. *See also* global assessment of functioning (GAF); global assessment of relational functioning (GARF)
- Multimodal Treatment Study of children with ADHD (MTA), 179
- Münchhausen, Karl, 160
- Munchausen syndrome, 160
- Myasthenia gravis
- clinical symptoms, 347
 - diagnosis, 347
 - treatment, 347
- Myelination and demyelination, 24–25
- Myocardial infarctions, from cocaine, 91–92
- Myotonic dystrophy, 26, 290, 348
- N-methyl-D-aspartate (NMDA). *See* glutamate
- Naloxone (Narcan), 251
- Naltrexone [ReVia (PO), Vivitrol (IM)]
- for pedophilia, 139
 - for substance-related disorders, 251–252
- Namenda (memantine), 254–255
- Narcissistic personality disorder, 164
- ICD-10 vs. *DSM-IV-TR*, 166
- Narcolepsy, 151
- Nardil (phenelzine), 229–230
- Nasal effects, from cocaine, 91–92
- National Alliance for the Mentally Ill (NAMI), 379
- National Institute of Mental Health Epidemiologic Catchment Area Survey (NIMH-ECA), 380
- Navane (thiothixene), 207
- Necrophilia, 138–139
- Necrosis vs. apoptosis, 19
- Nefazodone (Serzone), 228, 270
- Negative predictive value (NPV), 68
- Nelfinavir, 262
- Neologism, 51
- Nervous system infections
- AIDs related
 - CNS lymphoma, 292
 - complications presentation, 293
 - cryptococcus, 292
 - cytomegalovirus (CMV), 292–293
 - toxoplasmosis, 296
 - cerebrospinal fluid (CSF)
 - appearance/related pathology, 293
 - WBC counts, 293
 - herpes zoster, 293
 - HIV-related
 - dementia, 293–294
 - meningitis, 294
 - serum test, 294
 - Lyme disease, 294
 - meningitis
 - causes, 294–295
 - subacute/chronic, 295
 - neurosyphilis
 - clinical features, 295
 - serum tests, 295
 - progressive multifocal leukoencephalopathy, 293, 295–296
 - syphilis/stages of infection, 296
 - West Nile virus, 296
- Neurochemistry. *See also* neurotransmitters
- acetylcholine
 - muscarinic vs. receptors of, 16
 - synthesis/metabolism, 10
 - adrenergic alpha-1 antagonism (clinical effects), 10
 - adrenergic alpha-2 receptor, 10–11
 - biogenic amine neurotransmitters, 11
 - direct-coupled ion channels, 11–12
 - dopamine
 - nuclei (localization), 12
 - receptors, 12
 - synthesis, 12
 - tracts/physiological function, 13
 - G-protein coupled receptors, 14
 - gamma-aminobutyric acid
 - receptors, 13
 - synthesis, 13
 - glycine (*See* glycine)
 - histamine blockade (clinical effects), 14
 - melatonin, 15, 151–152
 - monoamine oxidase (MAO), 15
 - NMDA receptor, 16
 - norepinephrine synthesis, 16

- opioid regulation (of reward system), 17
- serotonin, 18
- Neuroleptic malignant syndrome (NMS), 198, 200, 201, 202, 204, 206, 271
- Neuroleptics
 - melatonin and, 152
 - in schizophrenia, 101
- Neurological complications, from cocaine, 91–92
- Neuromuscular disorders
 - amyotrophic lateral sclerosis (ALS), 343–344
 - Becker's dystrophy, 344
 - botulism, 344
 - carpal tunnel syndrome
 - clinical features, 344
 - pathophysiology/treatment, 345
 - Duchenne's muscular dystrophy, 346
 - Eaton-Lambert syndrome, 346
 - femoral nerve injury, 346
 - general weakness, causes, 345
 - Guillain-Barré syndrome, 293, 346–347
 - mitochondrial respiratory chain diseases, 347
 - myasthenia gravis
 - clinical symptoms, 347
 - diagnosis, 347
 - treatment, 347
 - myopathy vs. neuropathy, 348
 - myotonic dystrophy, 348
 - radial nerve injury, 349
 - sciatica, 349
 - tetanus, 349
 - ulnar nerve injury, 349
- Neuromuscular synapses, 25
- Neuronal heterotopia, 25
- Neurophysiology
 - action potential (mechanism), 22
 - apoptosis vs. necrosis, 19
 - arousal and wakefulness
 - anatomy, 19
 - electrophysiology, 20
 - evoked potential (EP), 20–21
 - excitotoxicity, 21
 - HPA and mental disorders, 21
 - memory
 - declarative, 22
 - formation and storage, 22–23
 - nondeclarative, 23
 - short vs. long-term, 24
 - working, 24
 - myelination/demyelination, 24–25
 - neuromuscular synapses, 25
 - neuronal migration, 25
 - neuronal pruning and reinforcement, 25
 - primitive reflex circuit, 25
 - resting potential, 25
 - synaptogenesis (critical times), 26
 - triphasic waves, 26
 - triplet (trinucleotide) repeat expansion, 26
- Neurosis, 51, 380
- Neurosyphilis
 - cerebrospinal fluid and, 293
 - clinical features, 295
 - serum tests, 295
- Neurotransmitters
 - excitatory, 15
 - inhibitory, 13, 15 (*See also* gamma-aminobutyric acid; glycine)
 - synthesis of, 11
- Neutropenia, from antipsychotics, 270
- Nevirapine, 262
- Nicot, Jean, 96
- Nicotine/nicotinic acetylcholine receptors, 16, 82, 83, 86, 96
- Nicotinic cholinergic, 11–12
- Nifedipine, 270
- Nihilism, 52
- NMDA glutamate receptor, 16, 25
- Nocturnal enuresis, 172
- Non-fluent aphasia, 341
- Non-rapid eye movement (NREM) sleep, 152
- Nondeclarative memory, 23
- Norepinephrine (NE), 10
 - in mood disorders, 115, 228
 - PTSD and, 122–123
 - reuptake blocking by cocaine, 82
 - synthesis of, 16
- Normal pressure hydrocephalus (NPH), 78
- Norpramin (desipramine), 221
- Nortriptyline (Aventyl/Pamelor)
 - for children and adolescents, 171
 - general information, 228–229
- Novelty seeking behavior, 166
- NREM sleep. *See* non-rapid eye movement (NREM) sleep
- Nucleus accumbens, 8, 9
- Null hypothesis (H_0), 67
 - associated errors, 67
 - chi-square test and, 65
- Nymphomania, 52
- Nystagmus, 88, 93
- Obesity hypoventilation syndrome (Pickwickian syndrome), 147
- Object constancy (in child development), 32
- Object permanence (infant development), 32
- Obsessive compulsive disorder (OCD), 164
 - epidemiology, 121
 - ICD-10 vs. *DSM-IV-TR*, 166
 - treatment, 121
 - vs. obsessive compulsive personality disorder, 167
- Obsessive compulsive personality disorder (OCPD), 167
- Oedipus complex, 33, 34, 42, 44
- Olanzapine (Zyprexa), 73, 202–203, 268, 271
- Olney, John, 21
- Operant (instrumental) conditioning, 44

460 Index

- Ophthalmoplegia, 88
 Opioids, 82
 dependence (etiology), 97
 intoxication and withdrawal, 97–98, 99
 pregnancy and, 97, 98
 pupillary constriction/dilation from, 93
 receptors, 98
 regulation of reward system, 17
 for restless leg syndrome, 154
 Oral contraceptive pills, 262–263
 Oral stage (of child development), 34
 Orap (pimozide), 204, 266
 Orbitofrontal cortex, 7, 8
 declarative memory and, 22
 Orgasmic disorder, 138
 in females, 136
 in males, 138
 Oxazepam (Serax), 237, 243, 245
 Oxcarbazepine, 117
 general information, 213
 pregnancy safety of, 213–214
 Oxymetazoline (Afrin), 264
- P-value (biostatics), 68
 Paliperidone (Invega), 203, 268, 271, 272
 Palsy, bulbar vs. pseudobulbar, 305
 Pamelor (nortriptyline), 171, 228–229
 Parahippocampal gyrus
 declarative memory and, 22
 schizophrenia and, 105
 Paramnesia, 52
 Paranoia/paranoid personality disorder, 105, 164, 167
 Paraphasias, 342
 Paraphilia NOS, 138–139. *See also* masochism and sadism
 epilepsy and, 301
 gender identity disorder vs., 137
 hypoxyphilia and, 138
 Paraphrenia, 106
 Parasomnias, 153
 Parental role modeling, 31
 Parkinson's disease, 75, 153, 267, 268
 dementia with Lewy body vs., 75–76, 334
 etiology, 335–336
 pathology, 336
 symptoms, 336
 treatment, 336
 Parnate (tranylcypromine), 232
 Paroxetine (Paxil/Paxil CR/Paxeva), 269–270
 adverse effects, 270
 for children and adolescents, 171
 general information, 229
 Partialism, 138–139
 Passive aggression, 52
 Pavlov, Ivan, 37–38
 Paxipam (halazepam), 237
 Pedophilia, 139
 Peduncular hallucinosis, 52
- Penis envy, 33, 34, 44
 Peptide neurotransmitters, 11
 Perceptual cortex, nondeclarative memory and, 23
 Pergolide (Permax), 154
 Perinatal anoxia, 106
 Perphenazine (Trilafon), 203–204
 Perseveration, 52, 59, 63
 Persistent perception disorder (flashbacks), 94
 Personality disorders
 antisocial personality disorder, 162
 treatment for, 162
 avoidant personality disorder, 162
 dependent vs., 164–165
 borderline personality disorder, 34, 163
 alternative terminology, 163
 treatment for, 163–164
 cluster A type, 164
 defense mechanisms for, 164
 dependent personality disorder, 164
 DSM-IV-TR categories, 161–162
 due to medical condition, 168
 epidemiology of, 165
 family history of, 165
 harm avoidance, 165
 histrionic personality disorder, 165–166
 novelty seeking, 166
 obsession vs. compulsion, 166
 OCD vs. OCPD, 167
 paranoid personality disorder, 167
 persistence, 167–168
 quality of life (QOL) associations, 168
 reward dependence, 168
 schizoid personality disorder, 168
 schizotypal personality disorder, 169
 twin studies, 169
 Peyote, 93–94
 Phallic stage (child development), 33, 34
 Pharmacokinetic interactions. *See also* adverse effects, evaluation and treatment for
 antiretroviral agents, 262
 carbamazepine, 262–263
 codeine, 263
 CYP450 interactions, by atypical antipsychotics, 263
 hepatic metabolism
 common inducers, 263
 common inhibitors, 263–264
 lamotrigine, 264
 lithium, 264
 MAOIs
 and over the counter medications, 264
 and serotonin elevating agents, 264–265
 phosphodiesterase type 5 inhibitors, 265
 pimozide, 263
 psychotropic drugs, protein binding characters, 265–266
 sertraline, 263

- valproic acid, 266
- ziprasidone, 266
- Phencyclidine (PCP)
 - intoxication
 - signs/symptoms, 98–99
 - treatment, 99
 - receptor mechanism, 99
- Phenelzine (Nardil), 229–230
- Phenobarbital, 263, 266
- Phentermine (Adipex-P), 260–261
- Phentolamine (central alpha blocker), 270
- Phenylephrine (Sudafed PE, Neo-Synephrine), 264
- Phenylketonuria, 288
- Phenytoin, 263, 266, 298
- Phobic disorders, 83
- Phonological disorder, 177
- Phosphodiesterase type 5 inhibitors, 265
- Phosphodiesterase type 5 (P5) inhibitors, 139–140
- Physostigmine (Antilirium), 75, 268
- Piaget, Jean, 27
 - adolescence stage (theory), 27
 - on child development
 - concrete operational stage, 29
 - developmental stages, 31
 - egocentrism stage, 30
 - object permanence, 32
 - preoperational stage, 33
 - preschool years, 29
 - sensorimotor stage, 34
- Piblokto (culture bound syndrome), 380
- Pica, 177
- Pick, Arnold, 78–79
- Pick's disease, 78–79
- Pickwickian syndrome (obesity hypoventilation syndrome), 147
- Pimozide (Orap), 204, 263, 266
 - for body dysmorphic disorder, 125–126
 - for Tourette's disorder, 179–180
- Pineal gland, melatonin secretion, 15
- Pituitary adenoma, 314
- Pleasure and reality principles, 44
- "Policeman-at-the-elbow law," 366
- Polyuria/polydipsia, induction by lithium, 212–213
- Positive and Negative Syndrome Scale (PANSS), 62
- Positive connotation (reframing), 193
- Positive predictive value (PPV)/negative predictive value (NPV), 68
- Posterior cerebral artery stroke, 308
- Posterior circulation TIAs, 308
- Postnatal growth retardation, 86
- Postpartum depression, 115
- Postpartum psychosis, 107
- Postpsychotic depressive disorder, 112
- Posttraumatic stress disorder (PTSD), 21, 36
 - biological changes, 122–123
 - clinical features, 123
 - comorbidities, 123
 - EMDR for, 123
 - pharmacotherapeutic treatment, 123
 - psychotherapies for, 123
 - stages, 123
- Prader, Andrea, 289
- Prader-Willi syndrome, 286, 289
- Pramipexole (Mirapex), 153, 154
- Prazepam (Centrex), 237
- Precox feeling, 52
- Preeclampsia, maternal, 106
- Prefrontal cortex, 8, 106
- Pregnancy
 - cocaine-use during, 92
 - ECT during, 280
 - opioid use during, 97, 98
 - safety of mood stabilizers, 213–214
- Prelinguistic memory, 23
- Premack, David, 45
- Premenstrual dysphoric disorder, 112
- Presynaptic alpha2-adrenergic agonists, 154
- Prevalence vs. incidence (biostatic), 68
- Primary sensory cortex, 8
- Pristiq (desvenlafaxine), 222
- Prochlorperazine (Compazine), 204–205
- Progressive multifocal leukoencephalopathy (PML), 293, 295–296
- Propranolol (Inderal, Inderal LA, InnoPran XL), 122, 263–264
 - adverse effects, 271–272
 - for phobias, 122
- ProSom (estazolam), 237, 240
- Protriptyline (Vivactil), 230
- Provigil (modafinil), 152
- Prozac (fluoxetine), 144–145, 171, 224–225, 264
- Pseudocholinesterase deficiency, 280
- Pseudodementia, 77–78, 115
- Pseudoephedrine (Sudafed), 264
- Pseudotumor cerebri
 - clinical features, 314
 - diagnosis, 315
 - headaches and, 323
 - risk factors, 315
 - treatment, 315
- Psilocybin, 93–94
- Psychiatric diagnosis, validity determination, 56
- Psychic determinism, 45
- Psychoanalytical psychotherapy, 192
- Psychodynamic psychotherapy
 - brief focal, 190
 - for eating disorders, 147–148
 - for PTSD, 123
 - termination of, 194
 - triangle of insight (component), 195
- Psychometric tools
 - abnormal involuntary movement scale (side effect assessment), 58
 - Beck Depression Inventory (BDI), 58
 - Bender gestalt test, 58–59
 - brief psychotic rating scale (BPRS), 59
 - clinical global improvement scale (CGI), 59

462 Index

- Psychometric tools (*Cont.*)
 construct validity, 60
 defensive functioning scale (DFS), 59
 Draw-A-Person test, 59–60
 global assessment of functioning (GAF), 60
 global assessment of relational functioning (GARF), 60
 Halstead-Reitan neuropsychological battery, 60
 Hamilton Rating Scale for Depression (HAM-D), 61
 Millon Clinical Multiaxial Inventory (MCMI), 61
 Mini-International Neuropsychiatric Interview (MINI), 61
 Minnesota Multiphasic Personality Inventory (MMPI), 61
 Positive and Negative Syndrome Scale (PANSS), 62
 reliability vs. validity, 62
 Rorschach Test, 62
 Social and Occupational Functioning Assessment Scale (SOFAS), 62
 Structured Clinical Interview for the DSM-IV (SCID), 62
 Thematic Apperception Test (TAT), 62
 Wada test, 63
 Wechsler Intelligence Scales, 63
 Wisconsin Card Sorting test, 63
 Word-Association, 63
 Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), 64
 Zung Self-Rating Depression Scale, 64
- Psychosis
 from cocaine use, 92
 from hallucinogens, 94
- Psychosocial theories
 abreaction, 36
 anal fixation, 36
 attribution theory, 37
 bonding vs. attachment, 37
 classical conditioning
 discrimination, 37
 extinction, 37–38
 generalization, 38
 cognitive dissonance, 38
 countertransference, 38
 defense mechanisms, 38–41
 double bind, 41
 downward drift hypothesis, 41
 dreams
 methods of disguise (Freud), 42
 psychoanalytic interpretation, 41–42
 ego psychology, 42
 learned helplessness, 43
 learning, in negative reinforcement, 43
 moral development (Kohlberg), 43
 Oedipus complex, 33, 34, 42, 44
 operant (instrumental) conditioning, 44
 personality development (in self psychology), 44
 pleasure/reality principles, 44
 Premack's principle, 45
 primary vs. secondary process, 45
 priming, 45
 psychic determinism, 45
 sensory deprivation, 45
 strange situation, 46
 therapist monkey (behavior phenomenon), 46
 transference, 46
 type A and B personalities, 46
- Psychosocial therapies, 117
 biofeedback, 189
 brief psychotherapy, 190, 195
 cognitive behavior therapy (*See* cognitive behavior therapy)
 confrontation, 190
 death, reaction to approach, 192
 dialectical behavior therapy, 163, 190–191
 enmeshment vs. disengagement, 191
 free association, 191
 interpersonal psychotherapy, 192
 mindfulness, 192
 psychiatric interview
 functions of, 192
 techniques used, 194
 psychoanalytical psychotherapy, 192
 psychodynamic psychotherapy, termination of, 194
 reframing (positive connotation), 193
 reparative therapy, 193
 resistance, 193
 short-term dynamic psychotherapy, 190
 structural family therapy, 193
 supportive psychotherapy, 193–194
 systematic desensitization, 194
 therapeutic neutrality, 194
 transference and countertransference, 194
 triangle of insight, 195
 triangulation, 195
- Psychosomatic disorders
 acute intermittent porphyria, 181
 adrenal insufficiency
 clinical features, 181–182
 etiology, 182
 treatment, 182
 agents causing QT/QTc prolongation, 182
 anxiety-related medical conditions, 187
 autoimmune diseases, 183
 celiac disease and psychosis, 183
 central pontine myelinolysis, 183
 Creutzfeldt-Jakob disease, 184
 in *DSM-IV-TR*, 181
 folate deficiency, 184
 functional pituitary adenoma, 184–185
 hemodialysis/psychiatric conditions and treatment, 185
 HIV/AIDS
 epidemiology, 185
 related psychiatric conditions, 185
 hyperglycemia, 186

- hyperparathyroidism and depression, 185–186
 hyperventilation syndrome, 186
 interferon treatment and mental disorders, 186
 Lyme disease, 186–187
 multiple sclerosis, 187
 peptic ulcer disorder, 187
 psoriasis, 188
 pulmonary condition and mental disorders, 188
 thyroid function tests, 188
- Psychosurgery
 efficacy/adverse effects, 280
 history/trends, 280–281
 indications, 280
 techniques, 281
- Psychotic disorders
 brief psychotic disorder, 101
 delusional disorder, 101–102
 dementia precox, 102
 DSM IV-TR categories, 100
 postpartum psychosis, 107
 psychoanalytical treatment for, 108
 schizophrenia (*See* schizophrenia)
- Psychotropic drugs. *See* individual drugs
- Puberty development
 in boys, 33
 in girls, 33–34
- Pupillary constriction, 93
- Putamen, 8
- Pyridoxine (vitamin B6), 13
- Quazepam (Doral), 237
- Quetiapine, 75, 205, 268, 271, 272
- Quinidine, 263
- Rabbit syndrome, 272
- Radial nerve injury, 349
- Ramelteon (Rozerem), 243–244
- Rape
 date rape, 351
 epidemiology of, 354
 of men, 353
 statistics
 of rapists, 354
 of victims, 354
 statutory rape, 369
 victim's psychological trip, 354
 of women, 353
- Rapid eye movement (REM) sleep, 152
- Rapprochement (reconciliation)stage (of child development), 34
- Razadyne/Razadyne ER (galantamine), 254
- Reactive attachment disorder (infancy/early childhood), 178
- Reading disorder, 178
- Reality principle, 44
- Recurrent brief depressive disorder, 112
- Reframing (positive connotation), 193
- Regents of the University of California, Tarasoff v.*, 369
- Regression (biostatic), 68
- Regression analysis method, choice determination, 65–66
- Reitan, Ralph M., 60
- Relative risk vs. odds ratio (biostatic), 68
- Reliability (biostatic), 69
- REM sleep. *See* rapid eye movement (REM) sleep
- Remeron/Remeron SolTab (mirtazapine), 11, 227
- Remission courses, of substance dependence, 83
- Reparative therapy, 193
- Repetitive transcranial magnetic stimulation (rTMS), 283
- Resistance, 193
- Resting potential, 25
- Restless leg syndrome, 151, 153, 154
 pharmacologic treatment, 154
 workup for, 154–155
- Restoril (temazepam), 237, 244, 245
- Reticular activating system, 8–9
 ascending, 19
- Retinitis, from encephalitis, 292–293
- Rett's disorder, 178
- Revatio (sildenafil), 265
- Reward dependence, 168
- Reward system, 9
- Risperidone, 73, 205–206
 adverse effects, 268, 271, 272
 for children and adolescents, 171
 paliperidone vs., 203
- Ritalin (methylphenidate), 125–126, 260
- Ritonavir, 262, 263
- Rivastigmine (Exelon, Exelon Patch), 255
- Robins, Eli, 56
- Robitussin (guaifenesin), 264
- Rolandic fissure, 7
- Romazicon (flumazenil), 250
- Ropinirole hydrochloride (Requip), 154, 155–156
- Rorschach, Hermann, 62
- Rosenman, Ray, 46
- Rozerem (ramelteon), 243–244
- Rumination disorder, 178
- Sadism (and masochism), 141
- Saquinavir, 262
- Sarno, John, 330
- Scatologia, telephone, 138–139
- Schizoid personality disorder, 168
- Schizophrenia, 21, 25, 164. *See also* brief psychotic disorder
 in adolescents, 171
 attentional deficits in, 105
 brain volume increase, 101
 brain volume reduction, 101
 developmental risks, 106
 diagnostic criteria, 102
 dopamine and
 hypothesis, 102
 type 2 receptors, 103
 double bind syndrome and, 41
 downward drift hypothesis and, 41

464 Index

- Schizophrenia (*Cont.*)
 epidemiology of, 103
 evoked potentials
 P50, 103
 P300, 103
 expressed emotions, 103
 in females, 108
 first-rank symptoms, 103–104
 formulations of
 Freud, 104
 Mahler, 105
 GABA in pathophysiology of, 104
 gender identity disorder vs., 137
 genetics of, 104
 glycine treatment for, 104
 late-onset schizophrenia, 105
 limbic system changes in, 105
 negative symptoms, 105
 neuronal density reduction in, 106
 paraphrenia, 106
 positive symptoms, 106–107
 prognosis of
 good indicators, 107
 poor indicators, 107–108
 statistics, 108
 smooth pursuit eye movements in, 108
 socio-cultural factors in, 109
 Schizophreniform disorder, 108
 Schizotypal personality disorder, 169
 Schneider, Kurt, 103–104
 Schwann, Theodor, 24–25
 Sciatica, 349
 Seckel, Helmut, 289–290
 Seckel syndrome, 289–290
 Secondary headaches, neuroimaging for, 323
 Secure attachment (of children), 27–28
 Seizure disorders
 antiepileptic drugs
 carbamazepine, 299
 causing renal stones, 298
 causing teratogenic defect, 298
 increasing seizure risks, 298
 inducing hepatic metabolism of oral contraceptives, 298
 not blocking Na⁺ channel, 298
 pregabalin for, 301–302
 epilepsy, 25
 absence seizures, 298, 299
 child-onset (*See* Lennox-Gastaut syndrome)
 drugs (first-line) for, 299, 301
 epidemiology of, 299
 eye deviation, direction of, 299
 frontal lobe partial seizures, 299
 grand mal seizures, 300
 interictal mood symptoms, 300
 interictal psychotic symptoms, 300
 occipital lobe partial seizures, 301
 parietal lobe partial seizures, 301
 partial seizures vs. panic attacks, 301
 personality changes from, 301
 postictal prolactin levels, 301
 pregnancy and, 299
 suicide and, 302
 surgical treatment for suicide and, 303
 temporal lobe focal seizures, 303
 Lennox-Gastaut syndrome, 300
 Selective mutism, 178
 Selective norepinephrine reuptake inhibitors (SNRIs), 116–117
 melatonin and, 152
 Selective serotonin reuptake inhibitors (SSRIs), 116–117, 263. *See also* fluoxetine; sertraline; tricyclic antidepressants
 adverse effects, 270
 for body dysmorphic disorder, 125–126
 for borderline personality disorder, 163–164
 for children and adolescents, 171
 for depersonalization, 133
 for generalized anxiety disorder, 120
 melatonin and, 152
 for obsessive compulsive disorder, 121
 for panic disorder, 122
 for pedophilia, 139
 for phobias, 122
 for PTSD, 123
 sexual dysfunction from, 141
 Selegiline (transdermal), 230–231
 Self psychology (Kohut), 44
 Seligman, Martin, 43
 Sensitivity vs. specificity (biostatic), 69
 Sensory deprivation (Hebb), 45
 Separation anxiety disorder, 178
 Separation-individuation stages (of child development), 34
 Serax (oxazepam), 237, 243, 245
 Serotonin, 10, 11. *See also* selective serotonin reuptake inhibitors (SSRIs)
 in mood disorders, 116
 nuclei (localization), 18
 receptors with clinical relevance, 18
 distribution of, 18
 reuptake blocking by cocaine, 82
 synthesis of, 18
 Serotonin syndrome, 273
 Sertraline (Zoloft), 263
 for children and adolescents, 171
 general information, 231
 Serzone (nefazodone), 228, 270
 Sexual and gender identity disorders
 DSM IV-TR categories, 100
 dysfunction
 from antidepressants, 141
 from cocaine use, 92
 dyspareunia, 136
 exhibitionism, 136
 females
 arousal disorder, 136
 orgasmic disorder, 136

- fetishism, 136
 frotteurism, 136
 gender identity disorder
 differential diagnosis, 137
 general information, 136–137
 hypoactive sexual desire disorder, 137
 hypoxyphilia, 138
 males
 erectile disorder, 138
 orgasmic disorder, 138
 masochism and sadism, 141
 paraphilia NOS, 138–139
 pedophilia, 139
 phases of sexual response, 139
 phosphodiesterase type 5 inhibitors, 139–140
 premature ejaculation, 140
 sexual arousal disorder
 medical evaluation, 140
 psychiatric evaluation for, 141
 treatment, 140
 sexual aversion disorder, 141
 transvestic fetishism, 141
 vaginismus, 141
 voyeurism, 142
 Yohimbine, 142
 Sexual harassment, 362
 Sexual reorientation therapy (reparative therapy), 193
 Shaken baby syndrome, 315
 Shared Psychotic Disorder (Folie à deux), 50
 Shen-k'uei/shenkui (culture bound syndrome), 381
 Shenjing shuairuo/neurasthenia (culture bound syndrome), 381
 Short-term (primary) memory, 24
 SIADH. *See* syndrome of inappropriate secretion of antidiuretic hormone
 Sibutramine (Meridia), 261
 Side effects of medication. *See* adverse effects, evaluation and treatment for
 Sildenafil (Viagra), 139–140, 265
 Silphen DM (dextromethorphan), 264
 Sinequan (doxepin), 222–223
 Sleep apnea, 151
 Sleep disorders. *See also* Angelman's syndrome
 brain wave measurements
 alpha waves, 150
 delta waves, 151
 theta waves, 156
 from cocaine use, 92
 daytime sleepiness, 151
 depression in, 116, 151
 dreams, 151
 DSM-IV-TR categories, 149
 effects of alcohol, 150
 melatonin, 151–152
 modafinil (Provigil) for, 152
 narcolepsy, 151, 152
 NREM sleep, 152
 orexins for, 153
 parasomnias, 153
 pramipexole (Mirapex) for, 153
 REM sleep, 152
 restless leg syndrome, 151, 153, 154
 pharmacologic treatment, 154
 workup for, 154–155
 ropinirole, 155–156
 sleep spindles and K-complexes, 156
 Smooth pursuit eye movements, in schizophrenia, 108
 Social and Occupational Functioning Assessment Scale (SOFAS), 62
 Social development model (Erikson), 30
 Somatization disorder
 diagnosis, 129
 malingering vs., 159
 principles of treatment, 129–130
 psychopharmacological treatment, 129
 psychotherapy for, 129
 vs. hypochondriasis, 129
 Somatoform disorders
 body dysmorphic disorder, 125–126
 Briquet's syndrome, 126
 conversion disorder, 126, 159
 DSM IV-TR categories, 125
 hypochondriasis
 course/prognosis, 126–127
 diagnosis, 127
 epidemiology, 127
 etiology (theories), 127–128
 vs. somatization disorder, 129
 Obsession de la honte du corps, 128
 pain disorders, 128
 pseudocyesis, 128
 pseudoseizure, 128
 somatization disorder (*See* somatization disorder)
 Sonata (zaleplon), 245–246
 Spastic cerebral palsy, 287
 Spinal cord anatomy (and related conditions)
 Brown-Sequard syndrome, 326
 cauda equina syndrome, 326
 cerebrospinal fluid/glucose level, 326
 cervicular radiculopathy, 328
 combined system disease, 328–329
 dermatomes, 329
 lateral spinothalamic tracts, 329–330
 lower back pain, 330
 meningocele/meningomyelocele, 331
 posterior columns, 331
 spinocerebellar ataxias (SCAs), 331
 spinocerebellar tracts, 331
 syringomyelia, 331
 tabes dorsalis, 332
 upper motor vs. lower motor neuron
 damages, 332
 Wallerian degeneration, 332
 Spinobulbar muscular dystrophy, 26, 290

466 Index

- Spinocerebellar ataxia type 1, 26, 290
 Spinocerebellar ataxias (SCAs), 331
 Spinocerebellar tracts, 331
 Spironolactone, 264
 Stalking, 363
 Standard deviation (SD), 69
 Status epilepticus, 84–85
 Statutory rape, 369
 Stelazine (trifluoperazine), 207
 Stereotypic movement disorder, 179
 Stevens-Johnson syndrome, 210, 299
 Stimulants
 amphetamines, 82, 91, 95, 256–257
 atomoxetine, 257
 benzphetamine, 257–258
 dextroamphetamines, 258
 lisdexamfetamine, 259
 methamphetamines, 91, 95, 259–260
 methylphenidate, 260
 phentermine, 260–261
 sibutramine, 261
 Stranger anxiety stage (of child development), 35, 46
 Strattera (atomoxetine), 257
 Striatum, 9
 Strokes and transient ischemic attacks (TIAs), 21
 anosognosia, 304
 anterior cerebral artery stroke, 304
 bulbar vs. pseudobulbar palsy, 305
 carotid artery TIAs, 305
 causes (of TIAs), 310
 cerebellar hemorrhage, 305
 cerebrovascular accidents, risk factors, 306
 internuclear ophthalmoplegia, 306
 intracranial hemorrhage, 306–307
 locked-in syndrome, 307
 middle cerebral artery stroke, 308
 posterior cerebral artery stroke, 308
 posterior circulation TIAs, 308
 psychiatric conditions associated with, 309
 subarachnoid hemorrhage, 309
 tissue plasminogen activator, 310
 transient global amnesia (TGA), 310
 Wallenberg's syndrome, 311
 Structural family therapy, 193
 Structured Clinical Interview for the DSM-IV (SCID), 62
 Structured Interview of Reported Symptoms (SIRS), 159
 Sturge, William, 290
 Sturge-Weber syndrome, 290
 Stuttering, 179
 Subarachnoid hemorrhage, 309
 Subcaudate tractotomy, 281
 Subcortical arteriosclerotic encephalopathy.
 See Binswanger's disease
 Subdural hematomas, 316
 Suboxone (buprenorphine), 248–249
 Substance related disorders, 21. *See also*
 addictions, non-alcoholic substance related disorders
 ADHD and, 177
 atypical depression and, 111
 bipolar disorder, rapid cycling and, 111
 HPA axis and, 21
 pharmacotherapy for
 acamprosate, 247–248
 buprenorphine, 248–249
 clonidine, 154, 173–174, 179–180, 249
 disulfiram, 249–250
 flumazenil, 250
 methadone, 250–251
 naloxone, 251
 naltrexone, 251–252
 varenicline, 252
 PTSD and, 123
 Substantia nigra, 9
 Subutex (buprenorphine), 248–249
 Succinylcholine, adverse effects during ECT, 279
 Sudafed (pseudoephedrine), 264
 Sudden death, from cocaine, 91–92
 Suicide. *See also* violent behavior
 antipsychotics: oral vs. injections, 351
 assessment of suicidal ideas, 355
 biological factors, 356
 biological therapeutics, 356
 chronological risks, 357
 completed/uncompleted, characteristics, 356
 contracts for prevention of, 355
 depression and, 352
 Durkheim's theory, 357
 emergency restraints, 352
 epidemiology, 357
 medical conditions increasing risk, 357
 mental illness and, 356
 National Strategy for Suicide Prevention, 358
 parasuicide, 352–353
 by physicians, 358
 psychiatric evaluation for, 358
 psychosocial protective factors, 358
 psychosocial risk factors, 358
 psychosocial theories, 359
 psychotherapy, in emergency settings, 353
 psychotic patients, interviews, 352
 schizophrenic patient's risks, 355
 Sundowning, 79
 Suomi, Stephen, 46
 Supportive psychotherapy, 193–194
 Supportive therapy
 for conversion disorder, 126
 for depersonalization disorder, 132
 for generalized anxiety disorder, 120
 Surmontil (trimipramine), 233
 Susto (culture bound syndrome), 381
 Sydenham, Thomas, 81, 336–337
 Sydenham's chorea, 336–337
 Sylvian fissure, 7

- Sylvius, Franciscus, 342
 Symmetrel (amantadine), 267
 Sympathetic nervous system (SNS), 2
 Synaptogenesis, critical times, 26
 Synesthesia, 52
 Syringomyelia, 331
- Tabes dorsalis, 332
 Tacrine (Cognex), 255
 Tadalafil (Cialis), 139–140, 265
 Taijin kyofusho (culture bound syndrome), 382
 Tangentiality/circumstantiality, 49
Tarasoff v. Regents of the University of California, 369
 Tardive dyskinesia
 anatomy, 273–274
 from antipsychotics, 73, 201, 202, 203, 204
 epidemiology, 274
 management, 274
 onset, 274
 pathology (hypothesized), 274
 risk factors, 275
 Tay-sachs disease, 288
 Tegretol/Tegretol XR. *See* carbamazepine
 Temazepam (Restoril), 237, 244, 245
 Temporal arteritis, 323
 Tension headache, 323–324
 Testosterone regulating medicine, 139
 Tetanus, 349
 Thalamus, 7, 8
 child development and, 30
 density reduction in schizophrenia, 106
 intralaminar nuclei, 19
 Thematic Apperception Test (TAT), 62
 Theophylline, 264, 282–283
 Therapist monkey (behavior phenomenon), 46
 Thiazide diuretics, 264
 Thioridazine (Mellaril), 206, 266
 Thiothixene (Navane), 207
 Thorazine (chlorpromazine), 266, 378
 Thoughts
 blocking, 53
 broadcasting/withdrawal, 53
 Tics, from cocaine, 91–92
 Tissue plasminogen activator (TPA), 310
 Tofranil/Tofranil PM (imipramine), 122, 225–226
 Tolbutamide, 266
 Tonic-clonic seizures, 84–85
 Topiramate
 for bulimia nervosa, 144–145
 general information, 214
 Tourette's disorder, 121, 173, 179–180, 204
 Toxic epidermal necrolysis, 210
 Toxoplasmosis infection, 293, 296
 Transcortical aphasia, 342
 Transcranial magnetic stimulation (TMS)/repetitive TMS (rTMS), 283
 Transference and countertransference, 194
 Transient global amnesia (TGA), 80, 93, 310
 Transient ischemic attacks (TIAs). *See* strokes and transient ischemic attacks (TIAs)
 Transient tic disorder, 180
 Transient visual hallucinations, 93
 Transvestic fetishism, 141
 Tranxene (clorazepate), 237
 Tranlycypromine (Parnate), 232
 Trazodone (Desyrel), 232–233
 Triangle of insight, 195
 Triangulation, 195
 Triazolam (Halcion), 237, 244
 Tricyclic antidepressants (TCAs), 263. *See also*
 amitriptyline; clomipramine;
 desipramine; doxepin; imipramine;
 nortriptyline; protriptyline
 adverse effects, 270
 for body dysmorphic disorder, 125–126
 cardiac monitoring for, 220
 for children and adolescents, 171
 for panic disorder, 122
 for PTSD, 123
 secondary amine vs. tertiary amine, 233
 Trifluoperazine (Stelazine), 207
 Trigeminal nerve, 2
 Trigeminal neuralgia
 clinical features, 324
 pathology, 324–325
 treatment, 325
 Trihexyphenidyl (Artane), 275
 Trilafon (perphenazine), 203–204
 Trileptal. *See* carbamazepine
 Trimipramine (Surmontil), 233
 Triphasic waves, 26
 Triplet (trinucleotide) repeat expansion, 26, 290
 Triptans for headaches, 325
 Trismus, 53
 Tryptophan, 18
 Turner, Henry, 291
 Turner's syndrome, 291
 Twin studies
 personality disorders, 169
 schizophrenia genetics and, 104
 Type A and B personalities, 46
- Ulnar nerve injury, 349
 Urophilia, 138–139
- Vaginismus, 141
 Vagus nerve stimulation, 284
 Validity (internal, external, construct), 70
 Validity of psychiatric diagnosis, 56
 Valium (diazepam), 237, 239–240
 Valproate, 262–264
 for absence (petit mal) seizure, 298
 adverse effects/safety caution, 215
 for bipolar disorder, 117

468 Index

- Valproate (*Cont.*)
 causing teratogenic defect, 298
 general information, 214–215
 for generalized epilepsies, 299
 pregnancy safety of, 213–214
- Vardenafil (Levitra), 139–140, 265
- Varenicline (Chantix), 252
- Vascular dementia, 77
- Venlafaxine (Effexor/Effexor XR), 269–270
 general information, 233–234
 for generalized anxiety disorder, 120
 sexual dysfunction from, 141
- Ventral tegmental area (VTA), of amygdala, 2, 9
- Veraguth, Otto, 118
- Veraguth's fold, 118
- Verapamil, 263–264
- Verbigeration, 53
- Viagra (sildenafil), 139–140, 265
- Violent behavior. *See also* suicide
 differential diagnosis, 359
 rape
 date rape, 351
 epidemiology of, 354
 of men, 353
 victim's psychological trip, 354
 of women, 353
 rape statistics
 of rapists, 354
 of victims, 354
 risk factors for homicide/aggressive behavior,
 354–355
- Visual hallucinations, 93
- Vivactil (protriptyline), 230
- Voices (arguing, discussing,
 commenting), 103–104
- Voyeurism, 142
- Vyvanse (lisdexamfetamine), 259
- Wada, Juhn, 63
- Wada test, 63
- Walker, Arthur, 287–288
- Wallenberg, Adolf, 311
- Wallenberg's syndrome, 311
- Wallerian, Augustus, 332
- Wallerian degeneration, 332
- Warfarin, 262–263, 266
- Watts, James, 280–281
- Weber, Frederick, 290
- Wechsler Intelligence Scales, 63
- Weight issues. *See* eating disorders and weight
 issues
- Wellbutrin (bupropion), 116–117,
 141, 219–220, 279
- Wernicke, Carl, 342
- Wernicke-Korsakoff syndrome, 88
- Wernicke's encephalopathy, 88
- West Nile virus, 296
- Willi, Heinrich, 289
- William, J., 291
- William's syndrome, 291
- Wilson's disease, 338
- Winnicott, Donald, 31, 32, 35
- Wisconsin Card Sorting test, 63
- With rapid cycling, 111
- Withdrawal
 from alcohol seizures, 84–85
 from amphetamines/cocaine, 89–90
 from benzodiazepines, 245
 from opioids, 97–98
- Word comprehension/production. *See* language
 milestones (child development)
- Working memory, 24
- Workmen's compensation issues, 370
- World Health Organization, 55
- Xanax (alprazolam), 236, 237
- Xyrem (gamma-hydroxybutyrate)(GHB), 91, 93,
 152, 158, 241–242
- Yale-Brown Obsessive-Compulsive Scale
 (Y-BOCS), 64
- Yohimbine, 11, 142
- Zaleplon (Sonata), 245–246
- Zar (culture bound syndrome), 382
- Zidovudine, 266
- Ziprasidone (Geodon), 208, 266, 268, 271, 272
- Zoloft (sertraline), 171, 231, 263
- Zolpidem (Ambien, Ambien CR), 246
- Zoophilia, 138–139
- Zung, William, 64
- Zung Self-Rating Depression Scale, 64
- Zyprexa (olanzapine), 73, 202–203, 268,
 271, 272